[{"orgOrder":0,"company":"Dogwood Therapeutics","sponsor":"Maxim Group","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Public Offering","leadProduct":"Tetrodotoxin","moa":"Sodium channel","graph1":"Neurology","graph2":"Phase II","graph3":"Dogwood Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Dogwood Therapeutics \/ Maxim Group","highestDevelopmentStatusID":"8","companyTruncated":"Dogwood Therapeutics \/ Maxim Group"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"||CB1 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"IGC Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"IGC Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"IGC Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ironwood Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Linaclotide","moa":"Guanylate cyclase C","graph1":"Neurology","graph2":"Phase II","graph3":"Ironwood Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ironwood Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ironwood Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ironwood Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Linaclotide","moa":"Guanylate cyclase C","graph1":"Neurology","graph2":"Phase II","graph3":"Ironwood Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ironwood Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ironwood Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Benuvia Therapeutics","sponsor":"VA CSRD","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Agreement","leadProduct":"Tetrahydrocannabinol","moa":"CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Benuvia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Benuvia Therapeutics \/ VA CSRD","highestDevelopmentStatusID":"8","companyTruncated":"Benuvia Therapeutics \/ VA CSRD"},{"orgOrder":0,"company":"CARA Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Difelikefalin Acetate","moa":"Kappa opioid receptor","graph1":"Neurology","graph2":"Phase II","graph3":"CARA Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"CARA Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CARA Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CARA Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Difelikefalin Acetate","moa":"Kappa opioid receptor","graph1":"Neurology","graph2":"Phase II","graph3":"CARA Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"CARA Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CARA Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Harmony Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Pitolisant Hydrochloride","moa":"H3 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Harmony Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Harmony Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Harmony Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Scilex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Lidocaine","moa":"NaV channel-alpha-subunit","graph1":"Neurology","graph2":"Phase II","graph3":"Scilex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical Patch","sponsorNew":"Scilex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Scilex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Scilex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Lidocaine","moa":"NaV channel-alpha-subunit","graph1":"Neurology","graph2":"Phase II","graph3":"Scilex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical Patch","sponsorNew":"Scilex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Scilex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Scilex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Lidocaine","moa":"NaV channel-alpha-subunit","graph1":"Neurology","graph2":"Phase II","graph3":"Scilex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Scilex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Scilex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Olorinab","moa":"CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Olorinab","moa":"CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Park Therapeutics","sponsor":"Tris Pharma Inc","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Acquisition","leadProduct":"Cebranopadol","moa":"NOP receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Park Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Park Therapeutics \/ Tris Pharma Inc","highestDevelopmentStatusID":"8","companyTruncated":"Park Therapeutics \/ Tris Pharma Inc"},{"orgOrder":0,"company":"Latigo Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"LTG-001","moa":"NaV1.8 Channel","graph1":"Neurology","graph2":"Phase II","graph3":"Latigo Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Latigo Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Latigo Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Magenta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"MGTA-456","moa":"CXCR-2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Magenta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Magenta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Magenta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Posdinemab","moa":"Tau aggregation","graph1":"Neurology","graph2":"Phase II","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Vaxxinity","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Public Offering","leadProduct":"UB-311","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase II","graph3":"Vaxxinity","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Vaxxinity \/ BofA Securities","highestDevelopmentStatusID":"8","companyTruncated":"Vaxxinity \/ BofA Securities"},{"orgOrder":0,"company":"Vaxxinity","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"UB-311","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase II","graph3":"Vaxxinity","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Vaxxinity \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaxxinity \/ Inapplicable"},{"orgOrder":0,"company":"Vaxxinity","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"UB-311","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase II","graph3":"Vaxxinity","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Vaxxinity \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaxxinity \/ Inapplicable"},{"orgOrder":0,"company":"Vaxxinity","sponsor":"University of Florida","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Collaboration","leadProduct":"UB-311","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase II","graph3":"Vaxxinity","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Vaxxinity \/ University of Florida","highestDevelopmentStatusID":"8","companyTruncated":"Vaxxinity \/ University of Florida"},{"orgOrder":0,"company":"Biogen","sponsor":"Ionis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"BIIB080","moa":"Tau aggregation","graph1":"Neurology","graph2":"Phase II","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Biogen \/ Ionis Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Biogen \/ Ionis Pharmaceuticals"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"BIIB080","moa":"Tau aggregation","graph1":"Neurology","graph2":"Phase II","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Autologous Mesenchymal Stem Cell Secreting Neurotrophic Factors Cell","moa":"Neurotrophic factor","graph1":"Neurology","graph2":"Phase II","graph3":"BrainStorm Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BrainStorm Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Autologous Mesenchymal Stem Cell Secreting Neurotrophic Factors Cell","moa":"Neurotrophic factor","graph1":"Neurology","graph2":"Phase II","graph3":"BrainStorm Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BrainStorm Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Alector","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"AL002","moa":"Amyloid-beta-plaque","graph1":"Neurology","graph2":"Phase II","graph3":"Alector","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alector \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alector \/ Inapplicable"},{"orgOrder":0,"company":"Alector","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"AL002","moa":"Amyloid-beta-plaque","graph1":"Neurology","graph2":"Phase II","graph3":"Alector","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alector \/ AbbVie Inc","highestDevelopmentStatusID":"8","companyTruncated":"Alector \/ AbbVie Inc"},{"orgOrder":0,"company":"Alector","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"AL101","moa":"Gamma-secretase","graph1":"Neurology","graph2":"Phase II","graph3":"Alector","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alector \/ GSK","highestDevelopmentStatusID":"8","companyTruncated":"Alector \/ GSK"},{"orgOrder":0,"company":"Cyclo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Hydroxypropyl-Beta Cyclodextrin","moa":"Cholesterol and lipid accumulation","graph1":"Neurology","graph2":"Phase II","graph3":"Cyclo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cyclo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cyclo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cyclo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Hydroxypropyl-Beta Cyclodextrin","moa":"Cholesterol and lipid accumulation","graph1":"Neurology","graph2":"Phase II","graph3":"Cyclo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cyclo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cyclo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Longeveron","sponsor":"Biorasi","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Laromestrocel","moa":"IL-10 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Longeveron","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Longeveron \/ Biorasi","highestDevelopmentStatusID":"8","companyTruncated":"Longeveron \/ Biorasi"},{"orgOrder":0,"company":"Cyclo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Hydroxypropyl-Beta Cyclodextrin","moa":"Cholesterol and lipid accumulation","graph1":"Neurology","graph2":"Phase II","graph3":"Cyclo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cyclo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cyclo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cyclo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Hydroxypropyl-Beta Cyclodextrin","moa":"Cholesterol and lipid accumulation","graph1":"Neurology","graph2":"Phase II","graph3":"Cyclo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cyclo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cyclo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Longeveron","sponsor":"Biorasi","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Laromestrocel","moa":"IL-10 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Longeveron","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Longeveron \/ Biorasi","highestDevelopmentStatusID":"8","companyTruncated":"Longeveron \/ Biorasi"},{"orgOrder":0,"company":"Longeveron","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Public Offering","leadProduct":"Laromestrocel","moa":"IL-10 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Longeveron","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Longeveron \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"8","companyTruncated":"Longeveron \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Longeveron","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Public Offering","leadProduct":"Laromestrocel","moa":"IL-10 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Longeveron","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Longeveron \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"8","companyTruncated":"Longeveron \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Longeveron","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Laromestrocel","moa":"IL-10 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Longeveron","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Longeveron \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Longeveron \/ Inapplicable"},{"orgOrder":0,"company":"Longeveron","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Laromestrocel","moa":"IL-10 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Longeveron","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Longeveron \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Longeveron \/ Inapplicable"},{"orgOrder":0,"company":"Longeveron","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Laromestrocel","moa":"IL-10 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Longeveron","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Longeveron \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Longeveron \/ Inapplicable"},{"orgOrder":0,"company":"Longeveron","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Laromestrocel","moa":"IL-10 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Longeveron","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Longeveron \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Longeveron \/ Inapplicable"},{"orgOrder":0,"company":"Longeveron","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Laromestrocel","moa":"IL-10 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Longeveron","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Longeveron \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Longeveron \/ Inapplicable"},{"orgOrder":0,"company":"Longeveron","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Laromestrocel","moa":"IL-10 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Longeveron","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Longeveron \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Longeveron \/ Inapplicable"},{"orgOrder":0,"company":"Longeveron","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Laromestrocel","moa":"IL-10 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Longeveron","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Longeveron \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Longeveron \/ Inapplicable"},{"orgOrder":0,"company":"Cyclo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Hydroxypropyl-Beta Cyclodextrin","moa":"Cholesterol and lipid accumulation","graph1":"Neurology","graph2":"Phase II","graph3":"Cyclo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cyclo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cyclo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cyclo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Hydroxypropyl-Beta Cyclodextrin","moa":"Cholesterol and lipid accumulation","graph1":"Neurology","graph2":"Phase II","graph3":"Cyclo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cyclo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cyclo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lonza Biologics Inc","sponsor":"Acumen Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Expanded Collaboration","leadProduct":"Sabirnetug","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase II","graph3":"Lonza Biologics Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lonza Biologics Inc \/ Acumen Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Lonza Biologics Inc \/ Acumen Pharmaceuticals"},{"orgOrder":0,"company":"Lonza Biologics Inc","sponsor":"Acumen Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Collaboration","leadProduct":"Sabirnetug","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase II","graph3":"Lonza Biologics Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lonza Biologics Inc \/ Acumen Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Lonza Biologics Inc \/ Acumen Pharmaceuticals"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Gosuranemab","moa":"Tau aggregation","graph1":"Neurology","graph2":"Phase II","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Vaccinex","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Public Offering","leadProduct":"Pepinemab","moa":"SEMA4D","graph1":"Neurology","graph2":"Phase II","graph3":"Vaccinex","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vaccinex \/ Alliance Global Partners","highestDevelopmentStatusID":"8","companyTruncated":"Vaccinex \/ Alliance Global Partners"},{"orgOrder":0,"company":"Vaccinex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Pepinemab","moa":"SEMA4D","graph1":"Neurology","graph2":"Phase II","graph3":"Vaccinex","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vaccinex \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaccinex \/ Inapplicable"},{"orgOrder":0,"company":"Vaccinex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Pepinemab","moa":"SEMA4D","graph1":"Neurology","graph2":"Phase II","graph3":"Vaccinex","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vaccinex \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaccinex \/ Inapplicable"},{"orgOrder":0,"company":"Vaccinex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Pepinemab","moa":"SEMA4D","graph1":"Neurology","graph2":"Phase II","graph3":"Vaccinex","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vaccinex \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaccinex \/ Inapplicable"},{"orgOrder":0,"company":"Vaccinex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Pepinemab","moa":"SEMA4D","graph1":"Neurology","graph2":"Phase II","graph3":"Vaccinex","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vaccinex \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaccinex \/ Inapplicable"},{"orgOrder":0,"company":"Vaccinex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Pepinemab","moa":"SEMA4D","graph1":"Neurology","graph2":"Phase II","graph3":"Vaccinex","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vaccinex \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaccinex \/ Inapplicable"},{"orgOrder":0,"company":"Vaccinex","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Private Placement","leadProduct":"Pepinemab","moa":"SEMA4D","graph1":"Neurology","graph2":"Phase II","graph3":"Vaccinex","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vaccinex \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Vaccinex \/ Undisclosed"},{"orgOrder":0,"company":"Vaccinex","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Private Placement","leadProduct":"Pepinemab","moa":"SEMA4D","graph1":"Neurology","graph2":"Phase II","graph3":"Vaccinex","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vaccinex \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Vaccinex \/ Undisclosed"},{"orgOrder":0,"company":"Neurotrope","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Bryostatin-1","moa":"PKC","graph1":"Neurology","graph2":"Phase II","graph3":"Neurotrope","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Neurotrope \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Neurotrope \/ Inapplicable"},{"orgOrder":0,"company":"Neurotrope","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Bryostatin-1","moa":"PKC","graph1":"Neurology","graph2":"Phase II","graph3":"Neurotrope","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Neurotrope \/ National Institutes of Health","highestDevelopmentStatusID":"8","companyTruncated":"Neurotrope \/ National Institutes of Health"},{"orgOrder":0,"company":"Neurotrope","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Bryostatin-1","moa":"PKC","graph1":"Neurology","graph2":"Phase II","graph3":"Neurotrope","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Neurotrope \/ National Institutes of Health","highestDevelopmentStatusID":"8","companyTruncated":"Neurotrope \/ National Institutes of Health"},{"orgOrder":0,"company":"Synaptogenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bryostatin-1","moa":"PKC","graph1":"Neurology","graph2":"Phase II","graph3":"Synaptogenix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Synaptogenix \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Synaptogenix \/ Inapplicable"},{"orgOrder":0,"company":"Synaptogenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bryostatin-1","moa":"PKC","graph1":"Neurology","graph2":"Phase II","graph3":"Synaptogenix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Synaptogenix \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Synaptogenix \/ Inapplicable"},{"orgOrder":0,"company":"Synaptogenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bryostatin-1","moa":"PKC","graph1":"Neurology","graph2":"Phase II","graph3":"Synaptogenix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Synaptogenix \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Synaptogenix \/ Inapplicable"},{"orgOrder":0,"company":"Synaptogenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bryostatin-1","moa":"PKC","graph1":"Neurology","graph2":"Phase II","graph3":"Synaptogenix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Synaptogenix \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Synaptogenix \/ Inapplicable"},{"orgOrder":0,"company":"Synaptogenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bryostatin-1","moa":"PKC","graph1":"Neurology","graph2":"Phase II","graph3":"Synaptogenix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Synaptogenix \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Synaptogenix \/ Inapplicable"},{"orgOrder":0,"company":"Synaptogenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Bryostatin-1","moa":"PKC","graph1":"Neurology","graph2":"Phase II","graph3":"Synaptogenix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Synaptogenix \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Synaptogenix \/ Inapplicable"},{"orgOrder":0,"company":"Synaptogenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bryostatin-1","moa":"PKC","graph1":"Neurology","graph2":"Phase II","graph3":"Synaptogenix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Synaptogenix \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Synaptogenix \/ Inapplicable"},{"orgOrder":0,"company":"Synaptogenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bryostatin-1","moa":"PKC","graph1":"Neurology","graph2":"Phase II","graph3":"Synaptogenix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Synaptogenix \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Synaptogenix \/ Inapplicable"},{"orgOrder":0,"company":"Synaptogenix","sponsor":"Katalyst Securities","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Private Placement","leadProduct":"Bryostatin-1","moa":"PKC","graph1":"Neurology","graph2":"Phase II","graph3":"Synaptogenix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Synaptogenix \/ Katalyst Securities","highestDevelopmentStatusID":"8","companyTruncated":"Synaptogenix \/ Katalyst Securities"},{"orgOrder":0,"company":"Synaptogenix","sponsor":"Katalyst Securities","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Private Placement","leadProduct":"Bryostatin-1","moa":"PKC","graph1":"Neurology","graph2":"Phase II","graph3":"Synaptogenix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Synaptogenix \/ Katalyst Securities","highestDevelopmentStatusID":"8","companyTruncated":"Synaptogenix \/ Katalyst Securities"},{"orgOrder":0,"company":"Synaptogenix","sponsor":"Katalyst Securities","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Private Placement","leadProduct":"Bryostatin-1","moa":"PKC","graph1":"Neurology","graph2":"Phase II","graph3":"Synaptogenix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Synaptogenix \/ Katalyst Securities","highestDevelopmentStatusID":"8","companyTruncated":"Synaptogenix \/ Katalyst Securities"},{"orgOrder":0,"company":"Synaptogenix","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bryostatin-1","moa":"PKC","graph1":"Neurology","graph2":"Phase II","graph3":"Synaptogenix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Synaptogenix \/ National Institutes of Health","highestDevelopmentStatusID":"8","companyTruncated":"Synaptogenix \/ National Institutes of Health"},{"orgOrder":0,"company":"Synaptogenix","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bryostatin-1","moa":"PKC","graph1":"Neurology","graph2":"Phase II","graph3":"Synaptogenix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Synaptogenix \/ National Institutes of Health","highestDevelopmentStatusID":"8","companyTruncated":"Synaptogenix \/ National Institutes of Health"},{"orgOrder":0,"company":"Vaccinex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Pepinemab","moa":"SEMA4D","graph1":"Neurology","graph2":"Phase II","graph3":"Vaccinex","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vaccinex \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaccinex \/ Inapplicable"},{"orgOrder":0,"company":"Vaccinex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Pepinemab","moa":"SEMA4D","graph1":"Neurology","graph2":"Phase II","graph3":"Vaccinex","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vaccinex \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaccinex \/ Inapplicable"},{"orgOrder":0,"company":"Worldwide Clinical Trials","sponsor":"Neurotrope","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Bryostatin-1","moa":"PKC","graph1":"Neurology","graph2":"Phase II","graph3":"Worldwide Clinical Trials","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Worldwide Clinical Trials \/ Neurotrope","highestDevelopmentStatusID":"8","companyTruncated":"Worldwide Clinical Trials \/ Neurotrope"},{"orgOrder":0,"company":"TrueBinding","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"TB006","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"TrueBinding","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"TrueBinding \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"TrueBinding \/ Inapplicable"},{"orgOrder":0,"company":"TrueBinding","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"TB006","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"TrueBinding","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"TrueBinding \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"TrueBinding \/ Inapplicable"},{"orgOrder":0,"company":"TrueBinding","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"TB006","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"TrueBinding","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"TrueBinding \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"TrueBinding \/ Inapplicable"},{"orgOrder":0,"company":"Pharmazz","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Sovateltide","moa":"ETB receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Pharmazz","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Pharmazz \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pharmazz \/ Inapplicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sodium Phenylbutyrate","moa":"||Mitochondria-mediated apoptosis","graph1":"Neurology","graph2":"Phase II","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amylyx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Amylyx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sodium Phenylbutyrate","moa":"||Mitochondria-mediated apoptosis","graph1":"Neurology","graph2":"Phase II","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amylyx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Amylyx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Tetra Therapeutics","sponsor":"Shionogi","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"Zatolmilast","moa":"PDE4D","graph1":"Neurology","graph2":"Phase II","graph3":"Tetra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tetra Therapeutics \/ Shionogi","highestDevelopmentStatusID":"8","companyTruncated":"Tetra Therapeutics \/ Shionogi"},{"orgOrder":0,"company":"Tetra Therapeutics","sponsor":"Shionogi","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Expanded Collaboration","leadProduct":"Zatolmilast","moa":"PDE4D","graph1":"Neurology","graph2":"Phase II","graph3":"Tetra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tetra Therapeutics \/ Shionogi","highestDevelopmentStatusID":"8","companyTruncated":"Tetra Therapeutics \/ Shionogi"},{"orgOrder":0,"company":"ChromaDex, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2023","type":"Inapplicable","leadProduct":"Nicotinamide Riboside Chloride","moa":"NAD","graph1":"Neurology","graph2":"Phase II","graph3":"ChromaDex, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ChromaDex, Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ChromaDex, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Ault Global Holdings","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Agreement","leadProduct":"Latozinemab","moa":"BDNF","graph1":"Neurology","graph2":"Phase II","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Alzamend Neuro \/ Ault Global Holdings","highestDevelopmentStatusID":"8","companyTruncated":"Alzamend Neuro \/ Ault Global Holdings"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Latozinemab","moa":"BDNF","graph1":"Neurology","graph2":"Phase II","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Alzamend Neuro \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alzamend Neuro \/ Inapplicable"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Latozinemab","moa":"BDNF","graph1":"Neurology","graph2":"Phase II","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Alzamend Neuro \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alzamend Neuro \/ Inapplicable"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Spartan Capital Securities","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Public Offering","leadProduct":"Latozinemab","moa":"BDNF","graph1":"Neurology","graph2":"Phase II","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Alzamend Neuro \/ Spartan Capital Securities","highestDevelopmentStatusID":"8","companyTruncated":"Alzamend Neuro \/ Spartan Capital Securities"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Public Offering","leadProduct":"Latozinemab","moa":"BDNF","graph1":"Neurology","graph2":"Phase II","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Alzamend Neuro \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alzamend Neuro \/ Undisclosed"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Altasciences Company Inc","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Agreement","leadProduct":"Latozinemab","moa":"BDNF","graph1":"Neurology","graph2":"Phase II","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Alzamend Neuro \/ Altasciences Company Inc","highestDevelopmentStatusID":"8","companyTruncated":"Alzamend Neuro \/ Altasciences Company Inc"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Altasciences Company Inc","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Agreement","leadProduct":"Latozinemab","moa":"BDNF","graph1":"Neurology","graph2":"Phase II","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Alzamend Neuro \/ Altasciences Company Inc","highestDevelopmentStatusID":"8","companyTruncated":"Alzamend Neuro \/ Altasciences Company Inc"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Digital Power Lending","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Financing","leadProduct":"Latozinemab","moa":"BDNF","graph1":"Neurology","graph2":"Phase II","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Alzamend Neuro \/ Digital Power Lending","highestDevelopmentStatusID":"8","companyTruncated":"Alzamend Neuro \/ Digital Power Lending"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Latozinemab","moa":"BDNF","graph1":"Neurology","graph2":"Phase II","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Alzamend Neuro \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alzamend Neuro \/ Inapplicable"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Latozinemab","moa":"BDNF","graph1":"Neurology","graph2":"Phase II","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Alzamend Neuro \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alzamend Neuro \/ Inapplicable"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Latozinemab","moa":"BDNF","graph1":"Neurology","graph2":"Phase II","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Alzamend Neuro \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alzamend Neuro \/ Inapplicable"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Latozinemab","moa":"BDNF","graph1":"Neurology","graph2":"Phase II","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Alzamend Neuro \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alzamend Neuro \/ Inapplicable"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Latozinemab","moa":"BDNF","graph1":"Neurology","graph2":"Phase II","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Alzamend Neuro \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alzamend Neuro \/ Inapplicable"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Latozinemab","moa":"BDNF","graph1":"Neurology","graph2":"Phase II","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Alzamend Neuro \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alzamend Neuro \/ Inapplicable"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Latozinemab","moa":"BDNF","graph1":"Neurology","graph2":"Phase II","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Alzamend Neuro \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alzamend Neuro \/ Inapplicable"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Latozinemab","moa":"BDNF","graph1":"Neurology","graph2":"Phase II","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Alzamend Neuro \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alzamend Neuro \/ Inapplicable"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Latozinemab","moa":"BDNF","graph1":"Neurology","graph2":"Phase II","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Alzamend Neuro \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alzamend Neuro \/ Inapplicable"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Private Placement","leadProduct":"Latozinemab","moa":"BDNF","graph1":"Neurology","graph2":"Phase II","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Alzamend Neuro \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alzamend Neuro \/ Undisclosed"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Latozinemab","moa":"BDNF","graph1":"Neurology","graph2":"Phase II","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Alzamend Neuro \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alzamend Neuro \/ Inapplicable"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Massachusetts General Hospital","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Partnership","leadProduct":"Latozinemab","moa":"BDNF","graph1":"Neurology","graph2":"Phase II","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Alzamend Neuro \/ Massachusetts General Hospital","highestDevelopmentStatusID":"8","companyTruncated":"Alzamend Neuro \/ Massachusetts General Hospital"},{"orgOrder":0,"company":"CervoMed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Neflamapimod","moa":"MAPK\/p38-alpha","graph1":"Neurology","graph2":"Phase II","graph3":"CervoMed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"CervoMed \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CervoMed \/ Inapplicable"},{"orgOrder":0,"company":"Karuna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Xanomeline","moa":"||M1\/M4 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Karuna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Karuna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Karuna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Neuphoria Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Collaboration","leadProduct":"MK-1167","moa":"nACh-alpha-7 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Neuphoria Therapeutics","amount2":0.48999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0.48999999999999999,"dosageForm":"Oral Capsule","sponsorNew":"Neuphoria Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Neuphoria Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"T3D Therapeutics","sponsor":"Alzheimer\u2019s Association","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"T3D-959","moa":"PPA-delta\/gamma receptor","graph1":"Neurology","graph2":"Phase II","graph3":"T3D Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"T3D Therapeutics \/ Alzheimer\u2019s Association","highestDevelopmentStatusID":"8","companyTruncated":"T3D Therapeutics \/ Alzheimer\u2019s Association"},{"orgOrder":0,"company":"T3D Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"T3D-959","moa":"PPA-delta\/gamma receptor","graph1":"Neurology","graph2":"Phase II","graph3":"T3D Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"T3D Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"T3D Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"T3D Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"T3D-959","moa":"PPA-delta\/gamma receptor","graph1":"Neurology","graph2":"Phase II","graph3":"T3D Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"T3D Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"T3D Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cognition Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Zervimesine","moa":"Sigma-2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Cognition Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cognition Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cognition Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cognition Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zervimesine","moa":"Sigma-2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Cognition Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cognition Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cognition Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cognition Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Zervimesine","moa":"Sigma-2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Cognition Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cognition Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cognition Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cognition Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Zervimesine","moa":"Sigma-2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Cognition Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cognition Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cognition Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cognition Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zervimesine","moa":"Sigma-2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Cognition Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cognition Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cognition Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cognition Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Zervimesine","moa":"Sigma-2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Cognition Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cognition Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cognition Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cognition Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Zervimesine","moa":"Sigma-2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Cognition Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cognition Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cognition Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cognition Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zervimesine","moa":"Sigma-2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Cognition Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cognition Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cognition Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cognition Therapeutics","sponsor":"National Institute on Aging","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Zervimesine","moa":"Sigma-2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Cognition Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cognition Therapeutics \/ National Institute on Aging","highestDevelopmentStatusID":"8","companyTruncated":"Cognition Therapeutics \/ National Institute on Aging"},{"orgOrder":0,"company":"Cognition Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Funding","leadProduct":"Zervimesine","moa":"Sigma-2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Cognition Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cognition Therapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"8","companyTruncated":"Cognition Therapeutics \/ National Institutes of Health"},{"orgOrder":0,"company":"Cognition Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"Zervimesine","moa":"Sigma-2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Cognition Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cognition Therapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"8","companyTruncated":"Cognition Therapeutics \/ National Institutes of Health"},{"orgOrder":0,"company":"Cognition Therapeutics","sponsor":"Titan Partners Group LLC","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Zervimesine","moa":"Sigma-2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Cognition Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cognition Therapeutics \/ Titan Partners Group LLC","highestDevelopmentStatusID":"8","companyTruncated":"Cognition Therapeutics \/ Titan Partners Group LLC"},{"orgOrder":0,"company":"Cognition Therapeutics","sponsor":"Titan Partners Group LLC","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Zervimesine","moa":"Sigma-2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Cognition Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cognition Therapeutics \/ Titan Partners Group LLC","highestDevelopmentStatusID":"8","companyTruncated":"Cognition Therapeutics \/ Titan Partners Group LLC"},{"orgOrder":0,"company":"KeifeRx","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Series A Financing","leadProduct":"Nilotinib","moa":"ABL1","graph1":"Neurology","graph2":"Phase II","graph3":"KeifeRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"KeifeRx \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"KeifeRx \/ Undisclosed"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"IGC Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"IGC Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"IGC Pharma \/ Inapplicable"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"IGC Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"IGC Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"IGC Pharma \/ Inapplicable"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"IGC Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"IGC Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"IGC Pharma \/ Inapplicable"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"IGC Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"IGC Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"IGC Pharma \/ Inapplicable"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"IGC Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"IGC Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"IGC Pharma \/ Inapplicable"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"IGC Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"IGC Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"IGC Pharma \/ Inapplicable"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"IGC Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"IGC Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"IGC Pharma \/ Inapplicable"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"IGC Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"IGC Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"IGC Pharma \/ Inapplicable"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Bradbury Asset Management","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Private Placement","leadProduct":"Tetrahydrocannabinol","moa":"||CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"IGC Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"IGC Pharma \/ Bradbury Asset Management","highestDevelopmentStatusID":"8","companyTruncated":"IGC Pharma \/ Bradbury Asset Management"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Bradbury Asset Management","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Private Placement","leadProduct":"Tetrahydrocannabinol","moa":"||CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"IGC Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"IGC Pharma \/ Bradbury Asset Management","highestDevelopmentStatusID":"8","companyTruncated":"IGC Pharma \/ Bradbury Asset Management"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"||CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"IGC Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"IGC Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"IGC Pharma \/ Inapplicable"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"||CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"IGC Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"IGC Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"IGC Pharma \/ Inapplicable"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"||CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"IGC Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"IGC Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"IGC Pharma \/ Inapplicable"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"IGC Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"IGC Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"IGC Pharma \/ Inapplicable"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"IGC Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"IGC Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"IGC Pharma \/ Inapplicable"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"IGC Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"IGC Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"IGC Pharma \/ Inapplicable"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"IGC Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"IGC Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"IGC Pharma \/ Inapplicable"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"IGC Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"IGC Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"IGC Pharma \/ Inapplicable"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"IGC Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"IGC Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"IGC Pharma \/ Inapplicable"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"O-Bank Co., Ltd.","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Financing","leadProduct":"Tetrahydrocannabinol","moa":"||CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"IGC Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"IGC Pharma \/ O-Bank Co., Ltd.","highestDevelopmentStatusID":"8","companyTruncated":"IGC Pharma \/ O-Bank Co., Ltd."},{"orgOrder":0,"company":"Spinogenix","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Funding","leadProduct":"SPG302","moa":"Synaptogenesis","graph1":"Neurology","graph2":"Phase II","graph3":"Spinogenix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Spinogenix \/ National Institutes of Health","highestDevelopmentStatusID":"8","companyTruncated":"Spinogenix \/ National Institutes of Health"},{"orgOrder":0,"company":"AmyriAD","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Raloxifene Hydrochloride","moa":"T-type calcium channel","graph1":"Neurology","graph2":"Phase II","graph3":"AmyriAD","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AmyriAD \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AmyriAD \/ Inapplicable"},{"orgOrder":0,"company":"AmyriAD","sponsor":"Societal CDMO","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Raloxifene Hydrochloride","moa":"T-type calcium channel","graph1":"Neurology","graph2":"Phase II","graph3":"AmyriAD","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AmyriAD \/ Societal CDMO","highestDevelopmentStatusID":"8","companyTruncated":"AmyriAD \/ Societal CDMO"},{"orgOrder":0,"company":"Scilex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tisolagiline","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Scilex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Scilex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Scilex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Spinogenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"SPG302","moa":"Synaptogenesis","graph1":"Neurology","graph2":"Phase II","graph3":"Spinogenix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Spinogenix \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Spinogenix \/ Inapplicable"},{"orgOrder":0,"company":"Spinogenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"SPG302","moa":"Synaptogenesis","graph1":"Neurology","graph2":"Phase II","graph3":"Spinogenix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Spinogenix \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Spinogenix \/ Inapplicable"},{"orgOrder":0,"company":"Societal CDMO","sponsor":"AmyriAD","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Raloxifene Hydrochloride","moa":"T-type calcium channel","graph1":"Neurology","graph2":"Phase II","graph3":"Societal CDMO","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Societal CDMO \/ AmyriAD","highestDevelopmentStatusID":"8","companyTruncated":"Societal CDMO \/ AmyriAD"},{"orgOrder":0,"company":"Cyclerion Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Zagociguat","moa":"sGC","graph1":"Neurology","graph2":"Phase II","graph3":"Cyclerion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cyclerion Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cyclerion Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Genetika","sponsor":"NeuroSense Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Collaboration","leadProduct":"Ciprofloxacin","moa":"||DNA gyrase","graph1":"Neurology","graph2":"Phase II","graph3":"Genetika","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Genetika \/ NeuroSense Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Genetika \/ NeuroSense Therapeutics"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Pegipanermin","moa":"TNF receptor","graph1":"Neurology","graph2":"Phase II","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"INmune Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"INmune Bio \/ Inapplicable"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Pegipanermin","moa":"TNF receptor","graph1":"Neurology","graph2":"Phase II","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"INmune Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"INmune Bio \/ Inapplicable"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Pegipanermin","moa":"TNF receptor","graph1":"Neurology","graph2":"Phase II","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"INmune Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"INmune Bio \/ Inapplicable"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Pegipanermin","moa":"TNF receptor","graph1":"Neurology","graph2":"Phase II","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"INmune Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"INmune Bio \/ Inapplicable"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Pegipanermin","moa":"TNF receptor","graph1":"Neurology","graph2":"Phase II","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"INmune Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"INmune Bio \/ Inapplicable"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Pegipanermin","moa":"TNF receptor","graph1":"Neurology","graph2":"Phase II","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"INmune Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"INmune Bio \/ Inapplicable"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Pegipanermin","moa":"TNF receptor","graph1":"Neurology","graph2":"Phase II","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"INmune Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"INmune Bio \/ Inapplicable"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Pegipanermin","moa":"TNF receptor","graph1":"Neurology","graph2":"Phase II","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"INmune Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"INmune Bio \/ Inapplicable"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Pegipanermin","moa":"TNF receptor","graph1":"Neurology","graph2":"Phase II","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"INmune Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"INmune Bio \/ Inapplicable"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Pegipanermin","moa":"TNF receptor","graph1":"Neurology","graph2":"Phase II","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"INmune Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"INmune Bio \/ Inapplicable"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Pegipanermin","moa":"TNF receptor","graph1":"Neurology","graph2":"Phase II","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"INmune Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"INmune Bio \/ Inapplicable"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Pegipanermin","moa":"TNF receptor","graph1":"Neurology","graph2":"Phase II","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"INmune Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"INmune Bio \/ Inapplicable"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Pegipanermin","moa":"TNF receptor","graph1":"Neurology","graph2":"Phase II","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"INmune Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"INmune Bio \/ Inapplicable"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Pegipanermin","moa":"TNF receptor","graph1":"Neurology","graph2":"Phase II","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"INmune Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"INmune Bio \/ Inapplicable"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Pegipanermin","moa":"TNF receptor","graph1":"Neurology","graph2":"Phase II","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"INmune Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"INmune Bio \/ Inapplicable"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Pegipanermin","moa":"TNF receptor","graph1":"Neurology","graph2":"Phase II","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"INmune Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"INmune Bio \/ Inapplicable"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Pegipanermin","moa":"TNF receptor","graph1":"Neurology","graph2":"Phase II","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"INmune Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"INmune Bio \/ Inapplicable"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Pegipanermin","moa":"TNF receptor","graph1":"Neurology","graph2":"Phase II","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"INmune Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"INmune Bio \/ Inapplicable"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Pegipanermin","moa":"TNF receptor","graph1":"Neurology","graph2":"Phase II","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"INmune Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"INmune Bio \/ Inapplicable"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Pegipanermin","moa":"TNF receptor","graph1":"Neurology","graph2":"Phase II","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"INmune Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"INmune Bio \/ Inapplicable"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Pegipanermin","moa":"TNF receptor","graph1":"Neurology","graph2":"Phase II","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"INmune Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"INmune Bio \/ Inapplicable"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Pegipanermin","moa":"TNF receptor","graph1":"Neurology","graph2":"Phase II","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"INmune Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"INmune Bio \/ Inapplicable"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Pegipanermin","moa":"TNF receptor","graph1":"Neurology","graph2":"Phase II","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"INmune Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"INmune Bio \/ Inapplicable"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Pegipanermin","moa":"TNF receptor","graph1":"Neurology","graph2":"Phase II","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"INmune Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"INmune Bio \/ Inapplicable"},{"orgOrder":0,"company":"INmune Bio","sponsor":"LifeSci Capital LLC","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2024","type":"Public Offering","leadProduct":"Pegipanermin","moa":"TNF receptor","graph1":"Neurology","graph2":"Phase II","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"INmune Bio \/ LifeSci Capital LLC","highestDevelopmentStatusID":"8","companyTruncated":"INmune Bio \/ LifeSci Capital LLC"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Maxim Group LLC","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2024","type":"Public Offering","leadProduct":"Pegipanermin","moa":"TNF receptor","graph1":"Neurology","graph2":"Phase II","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"INmune Bio \/ Maxim Group LLC","highestDevelopmentStatusID":"8","companyTruncated":"INmune Bio \/ Maxim Group LLC"},{"orgOrder":0,"company":"INmune Bio","sponsor":"OmniScience","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2024","type":"Partnership","leadProduct":"Pegipanermin","moa":"TNF receptor","graph1":"Neurology","graph2":"Phase II","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"INmune Bio \/ OmniScience","highestDevelopmentStatusID":"8","companyTruncated":"INmune Bio \/ OmniScience"},{"orgOrder":0,"company":"ADvantage Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Aluminium Hydroxide","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"ADvantage Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"ADvantage Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ADvantage Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ADvantage Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Aluminium Hydroxide","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"ADvantage Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"ADvantage Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ADvantage Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ADvantage Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Aluminium Hydroxide","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"ADvantage Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"ADvantage Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ADvantage Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ADvantage Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Aluminium Hydroxide","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"ADvantage Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"ADvantage Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ADvantage Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ADvantage Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Aluminium Hydroxide","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"ADvantage Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"ADvantage Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ADvantage Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Coya Therapeutics","sponsor":"Houston Methodist Research Institute","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2024","type":"Collaboration","leadProduct":"COYA 301","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Coya Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Coya Therapeutics \/ Houston Methodist Research Institute","highestDevelopmentStatusID":"8","companyTruncated":"Coya Therapeutics \/ Houston Methodist Research Institute"},{"orgOrder":0,"company":"Coya Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"COYA 301","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Coya Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Coya Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Coya Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Coya Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"COYA 301","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Coya Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Coya Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Coya Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sage Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"SAGE-718","moa":"NMDA receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Sage Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sage Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sage Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Coya Therapeutics","sponsor":"BTIG","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2024","type":"Private Placement","leadProduct":"COYA 302","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Coya Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Coya Therapeutics \/ BTIG","highestDevelopmentStatusID":"8","companyTruncated":"Coya Therapeutics \/ BTIG"},{"orgOrder":0,"company":"Coya Therapeutics","sponsor":"BTIG","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2024","type":"Private Placement","leadProduct":"COYA 302","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Coya Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Coya Therapeutics \/ BTIG","highestDevelopmentStatusID":"8","companyTruncated":"Coya Therapeutics \/ BTIG"},{"orgOrder":0,"company":"Coya Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"COYA 302","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Coya Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Coya Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Coya Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Coya Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"COYA 302","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Coya Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Coya Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Coya Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Coya Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"COYA 302","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Coya Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Coya Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Coya Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Eledon Pharmaceuticals","sponsor":"BVF Partners","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Private Placement","leadProduct":"Tegoprubart","moa":"CD40","graph1":"Neurology","graph2":"Phase II","graph3":"Eledon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eledon Pharmaceuticals \/ BVF Partners","highestDevelopmentStatusID":"8","companyTruncated":"Eledon Pharmaceuticals \/ BVF Partners"},{"orgOrder":0,"company":"Eledon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Tegoprubart","moa":"CD40","graph1":"Neurology","graph2":"Phase II","graph3":"Eledon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eledon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eledon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eledon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Tegoprubart","moa":"CD40","graph1":"Neurology","graph2":"Phase II","graph3":"Eledon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eledon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eledon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Novus Therapeutics, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Tegoprubart","moa":"CD40","graph1":"Neurology","graph2":"Phase II","graph3":"Novus Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Novus Therapeutics, Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Novus Therapeutics, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Anelixis Therapeutics","sponsor":"Novus Therapeutics, Inc","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Acquisition","leadProduct":"Tegoprubart","moa":"CD40","graph1":"Neurology","graph2":"Phase II","graph3":"Anelixis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Anelixis Therapeutics \/ Novus Therapeutics, Inc","highestDevelopmentStatusID":"8","companyTruncated":"Anelixis Therapeutics \/ Novus Therapeutics, Inc"},{"orgOrder":0,"company":"Coya Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"COYA 101","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Coya Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Coya Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Coya Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Coya Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"COYA 101","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Coya Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Coya Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Coya Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Coya Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"ALS001","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Coya Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Coya Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Coya Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Coya Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"ALS001","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Coya Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Coya Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Coya Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Coya Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Financing","leadProduct":"COYA 101","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Coya Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Coya Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Coya Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Revalesio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"RNS60","moa":"IntraCellular signaling","graph1":"Neurology","graph2":"Phase II","graph3":"Revalesio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Revalesio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Revalesio \/ Inapplicable"},{"orgOrder":0,"company":"Revalesio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"RNS60","moa":"IntraCellular signaling","graph1":"Neurology","graph2":"Phase II","graph3":"Revalesio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Revalesio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Revalesio \/ Inapplicable"},{"orgOrder":0,"company":"Revalesio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"RNS60","moa":"IntraCellular signaling","graph1":"Neurology","graph2":"Phase II","graph3":"Revalesio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Revalesio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Revalesio \/ Inapplicable"},{"orgOrder":0,"company":"Spinogenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"SPG302","moa":"Synaptogenesis","graph1":"Neurology","graph2":"Phase II","graph3":"Spinogenix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Spinogenix \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Spinogenix \/ Inapplicable"},{"orgOrder":0,"company":"Spinogenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"SPG302","moa":"Synaptogenesis","graph1":"Neurology","graph2":"Phase II","graph3":"Spinogenix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Spinogenix \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Spinogenix \/ Inapplicable"},{"orgOrder":0,"company":"Spinogenix","sponsor":"US Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Funding","leadProduct":"SPG302","moa":"Synaptogenesis","graph1":"Neurology","graph2":"Phase II","graph3":"Spinogenix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Spinogenix \/ US Department of Defense","highestDevelopmentStatusID":"8","companyTruncated":"Spinogenix \/ US Department of Defense"},{"orgOrder":0,"company":"Spinogenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"SPG302","moa":"Synaptogenesis","graph1":"Neurology","graph2":"Phase II","graph3":"Spinogenix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Spinogenix \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Spinogenix \/ Inapplicable"},{"orgOrder":0,"company":"Retrotope","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Linoleic Acid","moa":"Lipid peroxidation","graph1":"Neurology","graph2":"Phase II","graph3":"Retrotope","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Retrotope \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Retrotope \/ Inapplicable"},{"orgOrder":0,"company":"AI Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Apilimod mesylate","moa":"IL-12 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"AI Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AI Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AI Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"OrphAI Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Apilimod mesylate","moa":"IL-12 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"OrphAI Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"OrphAI Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"OrphAI Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Corcept Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Dazucorilant","moa":"Glucocorticoid receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Corcept Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Softgel Capsule","sponsorNew":"Corcept Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Corcept Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Corcept Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Dazucorilant","moa":"Glucocorticoid receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Corcept Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Softgel Capsule","sponsorNew":"Corcept Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Corcept Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Corcept Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Dazucorilant","moa":"Glucocorticoid receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Corcept Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Softgel Capsule","sponsorNew":"Corcept Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Corcept Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Denali Therapeutics","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"DNL788","moa":"RIPK1","graph1":"Neurology","graph2":"Phase II","graph3":"Denali Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Denali Therapeutics \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Denali Therapeutics \/ Sanofi"},{"orgOrder":0,"company":"Denali Therapeutics","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"DNL788","moa":"RIPK1","graph1":"Neurology","graph2":"Phase II","graph3":"Denali Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Denali Therapeutics \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Denali Therapeutics \/ Sanofi"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Swedish Orphan Biovitrum AB","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Pegcetacoplan","moa":"C3 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Apellis Pharmaceuticals \/ Swedish Orphan Biovitrum AB","highestDevelopmentStatusID":"8","companyTruncated":"Apellis Pharmaceuticals \/ Swedish Orphan Biovitrum AB"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Swedish Orphan Biovitrum AB","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Pegcetacoplan","moa":"C3 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Apellis Pharmaceuticals \/ Swedish Orphan Biovitrum AB","highestDevelopmentStatusID":"8","companyTruncated":"Apellis Pharmaceuticals \/ Swedish Orphan Biovitrum AB"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"NSI-566","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Palisade Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Palisade Bio \/ Inapplicable"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Utreloxastat","moa":"15-LOX","graph1":"Neurology","graph2":"Phase II","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PTC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PTC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Woolsey Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Fasudil","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Woolsey Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Woolsey Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Woolsey Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Woolsey Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Fasudil","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Woolsey Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Woolsey Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Woolsey Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Baudax Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"BX1000","moa":"nACh receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Baudax Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Baudax Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Baudax Bio \/ Inapplicable"},{"orgOrder":0,"company":"Baudax Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"BX1000","moa":"nACh receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Baudax Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Baudax Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Baudax Bio \/ Inapplicable"},{"orgOrder":0,"company":"Baudax Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"BX1000","moa":"nACh receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Baudax Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Baudax Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Baudax Bio \/ Inapplicable"},{"orgOrder":0,"company":"Baudax Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"BX1000","moa":"nACh receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Baudax Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Baudax Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Baudax Bio \/ Inapplicable"},{"orgOrder":0,"company":"Baudax Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"BX1000","moa":"nACh receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Baudax Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Baudax Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Baudax Bio \/ Inapplicable"},{"orgOrder":0,"company":"Cerevel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"CVL-871","moa":"D1\/D5 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Cerevel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cerevel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cerevel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cerevel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"CVL-871","moa":"D1\/D5 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Cerevel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cerevel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cerevel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"PaxMedica","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Suramin","moa":"Acidic fibroblast growth factor","graph1":"Neurology","graph2":"Phase II","graph3":"PaxMedica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PaxMedica \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"8","companyTruncated":"PaxMedica \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"PaxMedica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Suramin","moa":"Acidic fibroblast growth factor","graph1":"Neurology","graph2":"Phase II","graph3":"PaxMedica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PaxMedica \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PaxMedica \/ Inapplicable"},{"orgOrder":0,"company":"PaxMedica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Suramin","moa":"Acidic fibroblast growth factor","graph1":"Neurology","graph2":"Phase II","graph3":"PaxMedica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PaxMedica \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PaxMedica \/ Inapplicable"},{"orgOrder":0,"company":"PaxMedica","sponsor":"Lind Partners","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Financing","leadProduct":"Suramin","moa":"Acidic fibroblast growth factor","graph1":"Neurology","graph2":"Phase II","graph3":"PaxMedica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PaxMedica \/ Lind Partners","highestDevelopmentStatusID":"8","companyTruncated":"PaxMedica \/ Lind Partners"},{"orgOrder":0,"company":"PaxMedica","sponsor":"Vox Nova","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Suramin","moa":"Acidic fibroblast growth factor","graph1":"Neurology","graph2":"Phase II","graph3":"PaxMedica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PaxMedica \/ Vox Nova","highestDevelopmentStatusID":"8","companyTruncated":"PaxMedica \/ Vox Nova"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Oxytocin","moa":"CGRP receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Impel Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Olanzapine","moa":"5-HT2A\/D2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Impel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Impel Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Impel Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Axial Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"AB-2004","moa":"Gut microbiome","graph1":"Neurology","graph2":"Phase II","graph3":"Axial Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Axial Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Axial Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Axial Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"AB-2004","moa":"Gut microbiome","graph1":"Neurology","graph2":"Phase II","graph3":"Axial Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Axial Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Axial Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Axial Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"AB-2004","moa":"Gut microbiome","graph1":"Neurology","graph2":"Phase II","graph3":"Axial Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Axial Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Axial Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Axial Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"AB-2004","moa":"Gut microbiome","graph1":"Neurology","graph2":"Phase II","graph3":"Axial Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Axial Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Axial Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Axial Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"AB-2004","moa":"Gut microbiome","graph1":"Neurology","graph2":"Phase II","graph3":"Axial Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Axial Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Axial Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Axial Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"AB-2004","moa":"Gut microbiome","graph1":"Neurology","graph2":"Phase II","graph3":"Axial Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Axial Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Axial Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Axial Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"AB-2004","moa":"Gut microbiome","graph1":"Neurology","graph2":"Phase II","graph3":"Axial Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Axial Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Axial Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Axial Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"AB-2004","moa":"Gut microbiome","graph1":"Neurology","graph2":"Phase II","graph3":"Axial Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Axial Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Axial Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Yamo Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Methyltyrosine","moa":"Tyrosine hydroxylase","graph1":"Neurology","graph2":"Phase II","graph3":"Yamo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Yamo Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Yamo Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Yamo Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Methyltyrosine","moa":"Tyrosine hydroxylase","graph1":"Neurology","graph2":"Phase II","graph3":"Yamo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Yamo Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Yamo Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Yamo Pharmaceuticals","sponsor":"The Autism Impact Fund","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Financing","leadProduct":"Methyltyrosine","moa":"Tyrosine hydroxylase","graph1":"Neurology","graph2":"Phase II","graph3":"Yamo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Yamo Pharmaceuticals \/ The Autism Impact Fund","highestDevelopmentStatusID":"8","companyTruncated":"Yamo Pharmaceuticals \/ The Autism Impact Fund"},{"orgOrder":0,"company":"Zynerba Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Zynerba Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Gel","sponsorNew":"Zynerba Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Zynerba Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Zynerba Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Zynerba Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Gel","sponsorNew":"Zynerba Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Zynerba Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Zynerba Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Zynerba Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Gel","sponsorNew":"Zynerba Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Zynerba Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Zynerba Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Zynerba Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Gel","sponsorNew":"Zynerba Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Zynerba Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"EuMentis Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Series B Financing","leadProduct":"EM-113","moa":"NMDA receptor","graph1":"Neurology","graph2":"Phase II","graph3":"EuMentis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EuMentis Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"EuMentis Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Spine BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"SB-01","moa":"TGF-beta-1","graph1":"Neurology","graph2":"Phase II","graph3":"Spine BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intradiscal Injection","sponsorNew":"Spine BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Spine BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Eliem Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ETX-810","moa":"PPA-alpha receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Eliem Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eliem Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eliem Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Resiniferatoxin","moa":"TRPV1","graph1":"Neurology","graph2":"Phase II","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Epidural Injection","sponsorNew":"Sorrento Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sorrento Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Resiniferatoxin","moa":"TRPV1","graph1":"Neurology","graph2":"Phase II","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Epidural Injection","sponsorNew":"Sorrento Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sorrento Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Resiniferatoxin","moa":"TRPV1","graph1":"Neurology","graph2":"Phase II","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Epidural Injection","sponsorNew":"Sorrento Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sorrento Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Societal CDMO","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Societal CDMO","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Societal CDMO \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Societal CDMO \/ Undisclosed"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"4-Chlorokynurenine","moa":"||NMDA receptor","graph1":"Neurology","graph2":"Phase II","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"VistaGen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"VistaGen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Dogwood Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Tetrodotoxin","moa":"NaV Channel","graph1":"Neurology","graph2":"Phase II","graph3":"Dogwood Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Dogwood Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Dogwood Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Dogwood Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Tetrodotoxin","moa":"NaV Channel","graph1":"Neurology","graph2":"Phase II","graph3":"Dogwood Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Dogwood Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Dogwood Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Dogwood Therapeutics","sponsor":"WEX Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Merger","leadProduct":"Tetrodotoxin","moa":"NaV Channel","graph1":"Neurology","graph2":"Phase II","graph3":"Dogwood Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Dogwood Therapeutics \/ WEX Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Dogwood Therapeutics \/ WEX Pharmaceuticals"},{"orgOrder":0,"company":"Sonnet BioTherapeutics","sponsor":"Sonnet BioTherapeutics Holdings","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2020","type":"Merger","leadProduct":"Atexakin Alpha","moa":"IL-6 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Sonnet BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sonnet BioTherapeutics \/ Sonnet BioTherapeutics Holdings","highestDevelopmentStatusID":"8","companyTruncated":"Sonnet BioTherapeutics \/ Sonnet BioTherapeutics Holdings"},{"orgOrder":0,"company":"Sonnet BioTherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Atexakin Alpha","moa":"IL-6 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Sonnet BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sonnet BioTherapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sonnet BioTherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Emalex Bioscience","sponsor":"University of California","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ecopipam","moa":"D1 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Emalex Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Emalex Bioscience \/ University of California","highestDevelopmentStatusID":"8","companyTruncated":"Emalex Bioscience \/ University of California"},{"orgOrder":0,"company":"Emalex Bioscience","sponsor":"University of California","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ecopipam","moa":"D1 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Emalex Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Emalex Bioscience \/ University of California","highestDevelopmentStatusID":"8","companyTruncated":"Emalex Bioscience \/ University of California"},{"orgOrder":0,"company":"Neumentum","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"NTM-006","moa":"A3AR","graph1":"Neurology","graph2":"Phase II","graph3":"Neumentum","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Neumentum \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Neumentum \/ Inapplicable"},{"orgOrder":0,"company":"Neumentum","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"NTM-006","moa":"A3AR","graph1":"Neurology","graph2":"Phase II","graph3":"Neumentum","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Neumentum \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Neumentum \/ Inapplicable"},{"orgOrder":0,"company":"Aptinyx","sponsor":"K2 HealthVentures","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Financing","leadProduct":"NYX-2925","moa":"NMDA receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Aptinyx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aptinyx \/ K2 HealthVentures","highestDevelopmentStatusID":"8","companyTruncated":"Aptinyx \/ K2 HealthVentures"},{"orgOrder":0,"company":"Aptinyx","sponsor":"SVB Leerink","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"NYX-2925","moa":"NMDA receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Aptinyx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aptinyx \/ SVB Leerink","highestDevelopmentStatusID":"8","companyTruncated":"Aptinyx \/ SVB Leerink"},{"orgOrder":0,"company":"Aptinyx","sponsor":"Syneos Health","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"NYX-2925","moa":"NMDA receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Aptinyx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aptinyx \/ Syneos Health","highestDevelopmentStatusID":"8","companyTruncated":"Aptinyx \/ Syneos Health"},{"orgOrder":0,"company":"Ensysce Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Nafamostat Mesylate","moa":"||Mu opioid receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Ensysce Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Ensysce Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ensysce Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Ensysce Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Nafamostat Mesylate","moa":"||Mu opioid receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Ensysce Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Ensysce Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ensysce Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Ensysce Biosciences","sponsor":"Quotient Sciences","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Partnership","leadProduct":"Nafamostat Mesylate","moa":"||Mu opioid receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Ensysce Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Ensysce Biosciences \/ Quotient Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Ensysce Biosciences \/ Quotient Sciences"},{"orgOrder":0,"company":"Ensysce Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Nafamostat Mesylate","moa":"||Mu opioid receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Ensysce Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Ensysce Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ensysce Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Ensysce Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Oxycodone Prodrug","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Ensysce Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Ensysce Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ensysce Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Ensysce Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Oxycodone Prodrug","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Ensysce Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Ensysce Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ensysce Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Sustained Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Lidocaine Hydrochloride","moa":"Na channel-alpha-subunit","graph1":"Neurology","graph2":"Phase II","graph3":"Sustained Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sustained Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sustained Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AEON Biopharma","sponsor":"Daewoong Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2024","type":"Private Placement","leadProduct":"Prabotulinumtoxin A","moa":"ACh receptor","graph1":"Neurology","graph2":"Phase II","graph3":"AEON Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AEON Biopharma \/ Daewoong Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"AEON Biopharma \/ Daewoong Pharmaceutical"},{"orgOrder":0,"company":"AEON Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Prabotulinumtoxin A","moa":"ACh receptor","graph1":"Neurology","graph2":"Phase II","graph3":"AEON Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AEON Biopharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AEON Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"AEON Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Prabotulinumtoxin A","moa":"ACh receptor","graph1":"Neurology","graph2":"Phase II","graph3":"AEON Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AEON Biopharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AEON Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"AEON Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Prabotulinumtoxin A","moa":"ACh receptor","graph1":"Neurology","graph2":"Phase II","graph3":"AEON Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AEON Biopharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AEON Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"AEON Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Prabotulinumtoxin A","moa":"ACh receptor","graph1":"Neurology","graph2":"Phase II","graph3":"AEON Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AEON Biopharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AEON Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"AEON Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Prabotulinumtoxin A","moa":"ACh receptor","graph1":"Neurology","graph2":"Phase II","graph3":"AEON Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AEON Biopharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AEON Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"AEON Biopharma","sponsor":"Priveterra Acquisition Corp.","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2023","type":"Merger","leadProduct":"Prabotulinumtoxin A","moa":"ACh receptor","graph1":"Neurology","graph2":"Phase II","graph3":"AEON Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AEON Biopharma \/ Priveterra Acquisition Corp.","highestDevelopmentStatusID":"8","companyTruncated":"AEON Biopharma \/ Priveterra Acquisition Corp."},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Erasmus University Medical Center","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Hormone","year":"2023","type":"Collaboration","leadProduct":"Oxytocin","moa":"CGRP receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Erasmus University Medical Center","highestDevelopmentStatusID":"8","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Erasmus University Medical Center"},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Liechti Lab","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Collaboration","leadProduct":"LSD","moa":"5-HT1A\/2A receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Mind Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mind Medicine \/ Liechti Lab","highestDevelopmentStatusID":"8","companyTruncated":"Mind Medicine \/ Liechti Lab"},{"orgOrder":0,"company":"Aptinyx","sponsor":"CogState","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"NYX-458","moa":"NMDA receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Aptinyx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aptinyx \/ CogState","highestDevelopmentStatusID":"8","companyTruncated":"Aptinyx \/ CogState"},{"orgOrder":0,"company":"Sage Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"SAGE-718","moa":"NMDA receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Sage Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sage Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sage Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sage Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"SAGE-718","moa":"NMDA receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Sage Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sage Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sage Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CuraSen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"CST-103","moa":"ADRB2","graph1":"Neurology","graph2":"Phase II","graph3":"CuraSen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CuraSen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CuraSen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sage Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"SAGE-718","moa":"NMDA receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Sage Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sage Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sage Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Melt Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Midazolam","moa":"||GABAA receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Melt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Melt Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Melt Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Melt Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Midazolam","moa":"||GABAA receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Melt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Melt Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Melt Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Melt Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Midazolam","moa":"||GABAA receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Catalent Pharma Solutions \/ Melt Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Catalent Pharma Solutions \/ Melt Pharmaceuticals"},{"orgOrder":0,"company":"Melt Pharmaceuticals","sponsor":"Catalent Pharma Solutions","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"||NMDA receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Melt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Melt Pharmaceuticals \/ Catalent Pharma Solutions","highestDevelopmentStatusID":"8","companyTruncated":"Melt Pharmaceuticals \/ Catalent Pharma Solutions"},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Blarcamesine","moa":"Sigma-1 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Anavex Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Anavex Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Anavex Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Cognition Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zervimesine","moa":"Sigma-2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Cognition Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cognition Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cognition Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cognition Therapeutics","sponsor":"University of Miami","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zervimesine","moa":"Sigma-2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Cognition Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cognition Therapeutics \/ University of Miami","highestDevelopmentStatusID":"8","companyTruncated":"Cognition Therapeutics \/ University of Miami"},{"orgOrder":0,"company":"CuraSen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"CST-107","moa":"||ADRB2","graph1":"Neurology","graph2":"Phase II","graph3":"CuraSen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"CuraSen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CuraSen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CervoMed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Neflamapimod","moa":"MAPK\/p38-alpha","graph1":"Neurology","graph2":"Phase II","graph3":"CervoMed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CervoMed \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CervoMed \/ Inapplicable"},{"orgOrder":0,"company":"Longboard Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bexicaserin","moa":"5-HT2C receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Longboard Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Longboard Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Longboard Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Longboard Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Bexicaserin","moa":"5-HT2C receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Longboard Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Longboard Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Longboard Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Longboard Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Bexicaserin","moa":"5-HT2C receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Longboard Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Longboard Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Longboard Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Longboard Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Bexicaserin","moa":"5-HT2C receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Longboard Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Longboard Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Longboard Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Longboard Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Bexicaserin","moa":"5-HT2C receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Longboard Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Longboard Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Longboard Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Longboard Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Bexicaserin","moa":"5-HT2C receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Longboard Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Longboard Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Longboard Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Longboard Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Bexicaserin","moa":"5-HT2C receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Longboard Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Longboard Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Longboard Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Societal CDMO","sponsor":"Longboard Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Bexicaserin","moa":"5-HT2C receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Societal CDMO","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Societal CDMO \/ Longboard Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Societal CDMO \/ Longboard Pharmaceuticals"},{"orgOrder":0,"company":"Aptinyx","sponsor":"Rosalind Franklin University of Medicine and Science","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"NYX-2925","moa":"NMDA receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Aptinyx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aptinyx \/ Rosalind Franklin University of Medicine and Science","highestDevelopmentStatusID":"8","companyTruncated":"Aptinyx \/ Rosalind Franklin University of Medicine and Science"},{"orgOrder":0,"company":"Aptinyx","sponsor":"Syneos Health","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"NYX-2925","moa":"NMDA receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Aptinyx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aptinyx \/ Syneos Health","highestDevelopmentStatusID":"8","companyTruncated":"Aptinyx \/ Syneos Health"},{"orgOrder":0,"company":"Aptinyx","sponsor":"Syneos Health","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"NYX-2925","moa":"NMDA receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Aptinyx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aptinyx \/ Syneos Health","highestDevelopmentStatusID":"8","companyTruncated":"Aptinyx \/ Syneos Health"},{"orgOrder":0,"company":"Eliem Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ETX-810","moa":"PPA-alpha receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Eliem Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eliem Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eliem Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Eliem Therapeutics","sponsor":"Intermediate Capital Group","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Series B Financing","leadProduct":"ETX-810","moa":"PPA-alpha receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Eliem Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eliem Therapeutics \/ Intermediate Capital Group","highestDevelopmentStatusID":"8","companyTruncated":"Eliem Therapeutics \/ Intermediate Capital Group"},{"orgOrder":0,"company":"Eliem Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Public Offering","leadProduct":"ETX-810","moa":"PPA-alpha receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Eliem Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eliem Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Eliem Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"NeuroBo Pharmaceuticals","sponsor":"Gemphire Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Merger","leadProduct":"Dioscorea Extract","moa":"IL-6 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroBo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"NeuroBo Pharmaceuticals \/ Gemphire Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"NeuroBo Pharmaceuticals \/ Gemphire Therapeutics"},{"orgOrder":0,"company":"NeuroBo Pharmaceuticals","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"Dioscorea Extract","moa":"IL-6 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroBo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"NeuroBo Pharmaceuticals \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"8","companyTruncated":"NeuroBo Pharmaceuticals \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"NeuroBo Pharmaceuticals","sponsor":"MThera Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Dioscorea Extract","moa":"IL-6 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroBo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"NeuroBo Pharmaceuticals \/ MThera Pharma","highestDevelopmentStatusID":"8","companyTruncated":"NeuroBo Pharmaceuticals \/ MThera Pharma"},{"orgOrder":0,"company":"NeuroBo Pharmaceuticals","sponsor":"MThera Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Dioscorea Extract","moa":"IL-6 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroBo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"NeuroBo Pharmaceuticals \/ MThera Pharma","highestDevelopmentStatusID":"8","companyTruncated":"NeuroBo Pharmaceuticals \/ MThera Pharma"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Suzetrigine","moa":"NaV1.8 Channel","graph1":"Neurology","graph2":"Phase II","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"JanOne","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sodium Nitrite","moa":"Vasodilator","graph1":"Neurology","graph2":"Phase II","graph3":"JanOne","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"JanOne \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"JanOne \/ Inapplicable"},{"orgOrder":0,"company":"JanOne","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sodium Nitrite","moa":"Vasodilator","graph1":"Neurology","graph2":"Phase II","graph3":"JanOne","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"JanOne \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"JanOne \/ Inapplicable"},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pilavapadin","moa":"AAK-1","graph1":"Neurology","graph2":"Phase II","graph3":"Lexicon pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Lexicon pharmaceuticals \/ Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"Lexicon pharmaceuticals \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pilavapadin","moa":"AAK-1","graph1":"Neurology","graph2":"Phase II","graph3":"Lexicon pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Lexicon pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lexicon pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pilavapadin","moa":"AAK-1","graph1":"Neurology","graph2":"Phase II","graph3":"Lexicon pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Lexicon pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lexicon pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pilavapadin","moa":"AAK-1","graph1":"Neurology","graph2":"Phase II","graph3":"Lexicon pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Lexicon pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lexicon pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Pilavapadin","moa":"AAK-1","graph1":"Neurology","graph2":"Phase II","graph3":"Lexicon pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Lexicon pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lexicon pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pilavapadin","moa":"AAK-1","graph1":"Neurology","graph2":"Phase II","graph3":"Lexicon pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Lexicon pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lexicon pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Private Placement","leadProduct":"Pilavapadin","moa":"AAK-1","graph1":"Neurology","graph2":"Phase II","graph3":"Lexicon pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Lexicon pharmaceuticals \/ Jefferies","highestDevelopmentStatusID":"8","companyTruncated":"Lexicon pharmaceuticals \/ Jefferies"},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Pilavapadin","moa":"AAK-1","graph1":"Neurology","graph2":"Phase II","graph3":"Lexicon pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Lexicon pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lexicon pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Pilavapadin","moa":"AAK-1","graph1":"Neurology","graph2":"Phase II","graph3":"Lexicon pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Lexicon pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lexicon pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Pilavapadin","moa":"AAK-1","graph1":"Neurology","graph2":"Phase II","graph3":"Lexicon pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lexicon pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lexicon pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Buntanetap","moa":"APP","graph1":"Neurology","graph2":"Phase II","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Annovis Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Annovis Bio \/ Inapplicable"},{"orgOrder":0,"company":"Alector","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"AL002","moa":"Amyloid-beta-plaque","graph1":"Neurology","graph2":"Phase II","graph3":"Alector","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alector \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alector \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Prasinezumab","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase II","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genentech \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"8","companyTruncated":"Genentech \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Stoke Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Zorevunersen Sodium","moa":"NaV1.1 channel","graph1":"Neurology","graph2":"Phase II","graph3":"Stoke Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Stoke Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Stoke Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Stoke Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Zorevunersen Sodium","moa":"NaV1.1 channel","graph1":"Neurology","graph2":"Phase II","graph3":"Stoke Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Stoke Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Stoke Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Stoke Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Zorevunersen Sodium","moa":"NaV1.1 channel","graph1":"Neurology","graph2":"Phase II","graph3":"Stoke Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Stoke Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Stoke Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Stoke Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Zorevunersen Sodium","moa":"NaV1.1 channel","graph1":"Neurology","graph2":"Phase II","graph3":"Stoke Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Stoke Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Stoke Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Stoke Therapeutics","sponsor":"Biogen","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Collaboration","leadProduct":"Zorevunersen Sodium","moa":"NaV1.1 channel","graph1":"Neurology","graph2":"Phase II","graph3":"Stoke Therapeutics","amount2":0.55000000000000004,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0.55000000000000004,"dosageForm":"Intrathecal Injection","sponsorNew":"Stoke Therapeutics \/ Biogen","highestDevelopmentStatusID":"8","companyTruncated":"Stoke Therapeutics \/ Biogen"},{"orgOrder":0,"company":"Stoke Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Zorevunersen Sodium","moa":"NaV1.1 channel","graph1":"Neurology","graph2":"Phase II","graph3":"Stoke Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Stoke Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Stoke Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Stoke Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Zorevunersen Sodium","moa":"NaV1.1 channel","graph1":"Neurology","graph2":"Phase II","graph3":"Stoke Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Stoke Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Stoke Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Stoke Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Zorevunersen Sodium","moa":"NaV1.1 channel","graph1":"Neurology","graph2":"Phase II","graph3":"Stoke Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Stoke Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Stoke Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Stoke Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Zorevunersen Sodium","moa":"NaV1.1 channel","graph1":"Neurology","graph2":"Phase II","graph3":"Stoke Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Stoke Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Stoke Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Stoke Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Zorevunersen Sodium","moa":"NaV1.1 channel","graph1":"Neurology","graph2":"Phase II","graph3":"Stoke Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Stoke Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Stoke Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Stoke Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Public Offering","leadProduct":"Zorevunersen Sodium","moa":"NaV1.1 channel","graph1":"Neurology","graph2":"Phase II","graph3":"Stoke Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Stoke Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"8","companyTruncated":"Stoke Therapeutics \/ J.P. Morgan"},{"orgOrder":0,"company":"Stoke Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Public Offering","leadProduct":"Zorevunersen Sodium","moa":"NaV1.1 channel","graph1":"Neurology","graph2":"Phase II","graph3":"Stoke Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Stoke Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"8","companyTruncated":"Stoke Therapeutics \/ J.P. Morgan"},{"orgOrder":0,"company":"Epygenix Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Clemizole hydrochloride","moa":"H1 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Epygenix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Epygenix Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Epygenix Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Epygenix Therapeutics","sponsor":"GreenLight Clinical","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Clemizole hydrochloride","moa":"H1 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Epygenix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Epygenix Therapeutics \/ GreenLight Clinical","highestDevelopmentStatusID":"8","companyTruncated":"Epygenix Therapeutics \/ GreenLight Clinical"},{"orgOrder":0,"company":"Epygenix Therapeutics","sponsor":"Harmony Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"Clemizole hydrochloride","moa":"H1 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Epygenix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Epygenix Therapeutics \/ Harmony Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"Epygenix Therapeutics \/ Harmony Biosciences"},{"orgOrder":0,"company":"Epygenix Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Clemizole hydrochloride","moa":"H1 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Epygenix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Epygenix Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Epygenix Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Epygenix Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Clemizole hydrochloride","moa":"H1 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Epygenix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Epygenix Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Epygenix Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ovid Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Soticlestat","moa":"CH24H","graph1":"Neurology","graph2":"Phase II","graph3":"Ovid Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ovid Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ovid Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Praxis Precision Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Relutrigine","moa":"NaV Channel","graph1":"Neurology","graph2":"Phase II","graph3":"Praxis Precision Medicines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Praxis Precision Medicines \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Praxis Precision Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Rapport Therapeutics","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"RAP-219","moa":"AMPA receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Rapport Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rapport Therapeutics \/ Goldman Sachs & Co","highestDevelopmentStatusID":"8","companyTruncated":"Rapport Therapeutics \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"Rapport Therapeutics","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"RAP-219","moa":"AMPA receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Rapport Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rapport Therapeutics \/ Goldman Sachs & Co","highestDevelopmentStatusID":"8","companyTruncated":"Rapport Therapeutics \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"Rapport Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"RAP-219","moa":"AMPA receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Rapport Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rapport Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Rapport Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cerebral Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sodium Valproate","moa":"NaV Channel","graph1":"Neurology","graph2":"Phase II","graph3":"Cerebral Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracerebroventricular Implant","sponsorNew":"Cerebral Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cerebral Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cerebral Therapeutics","sponsor":"Lynx1 Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Series C Financing","leadProduct":"Sodium Valproate","moa":"NaV Channel","graph1":"Neurology","graph2":"Phase II","graph3":"Cerebral Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracerebroventricular Implant","sponsorNew":"Cerebral Therapeutics \/ Lynx1 Capital Management","highestDevelopmentStatusID":"8","companyTruncated":"Cerebral Therapeutics \/ Lynx1 Capital Management"},{"orgOrder":0,"company":"Cerebral Therapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Series B Financing","leadProduct":"Sodium Valproate","moa":"NaV Channel","graph1":"Neurology","graph2":"Phase II","graph3":"Cerebral Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracerebroventricular Implant","sponsorNew":"Cerebral Therapeutics \/ RA Capital Management","highestDevelopmentStatusID":"8","companyTruncated":"Cerebral Therapeutics \/ RA Capital Management"},{"orgOrder":0,"company":"Virpax Pharmaceuticals","sponsor":"Innovation Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Virpax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Powder for Inhalation","sponsorNew":"Virpax Pharmaceuticals \/ Innovation Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Virpax Pharmaceuticals \/ Innovation Pharmaceuticals"},{"orgOrder":0,"company":"Virpax Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Virpax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Powder for Inhalation","sponsorNew":"Virpax Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Virpax Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Virpax Pharmaceuticals","sponsor":"Nanomerics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Licensing Agreement","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Virpax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Powder for Inhalation","sponsorNew":"Virpax Pharmaceuticals \/ Nanomerics","highestDevelopmentStatusID":"8","companyTruncated":"Virpax Pharmaceuticals \/ Nanomerics"},{"orgOrder":0,"company":"Virpax Pharmaceuticals","sponsor":"Thinkequity","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Virpax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Powder for Inhalation","sponsorNew":"Virpax Pharmaceuticals \/ Thinkequity","highestDevelopmentStatusID":"8","companyTruncated":"Virpax Pharmaceuticals \/ Thinkequity"},{"orgOrder":0,"company":"Praxis Precision Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"PRAX-628","moa":"NaV Channel","graph1":"Neurology","graph2":"Phase II","graph3":"Praxis Precision Medicines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Praxis Precision Medicines \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Praxis Precision Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Praxis Precision Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"PRAX-628","moa":"NaV Channel","graph1":"Neurology","graph2":"Phase II","graph3":"Praxis Precision Medicines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Praxis Precision Medicines \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Praxis Precision Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Praxis Precision Medicines","sponsor":"Piper Sandler","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"PRAX-628","moa":"NaV Channel","graph1":"Neurology","graph2":"Phase II","graph3":"Praxis Precision Medicines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Praxis Precision Medicines \/ Piper Sandler","highestDevelopmentStatusID":"8","companyTruncated":"Praxis Precision Medicines \/ Piper Sandler"},{"orgOrder":0,"company":"Praxis Precision Medicines","sponsor":"Piper Sandler","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"PRAX-628","moa":"NaV Channel","graph1":"Neurology","graph2":"Phase II","graph3":"Praxis Precision Medicines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Praxis Precision Medicines \/ Piper Sandler","highestDevelopmentStatusID":"8","companyTruncated":"Praxis Precision Medicines \/ Piper Sandler"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Addex Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ADX71149","moa":"||mGlu2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Addex Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Addex Therapeutics"},{"orgOrder":0,"company":"Cerevel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Darigabat","moa":"GABAA receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Cerevel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cerevel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cerevel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cerevel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Darigabat","moa":"GABAA receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Cerevel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cerevel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cerevel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ovid Therapeutics","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Termination","leadProduct":"Soticlestat","moa":"CH24H","graph1":"Neurology","graph2":"Phase II","graph3":"Ovid Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ovid Therapeutics \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Ovid Therapeutics \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Bright Minds Biosciences","sponsor":"Asset Management","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Private Placement","leadProduct":"BMB-101","moa":"5-HT2C receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Bright Minds Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bright Minds Biosciences \/ Asset Management","highestDevelopmentStatusID":"8","companyTruncated":"Bright Minds Biosciences \/ Asset Management"},{"orgOrder":0,"company":"Bright Minds Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"BMB-101","moa":"5-HT2C receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Bright Minds Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bright Minds Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Bright Minds Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Bright Minds Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"BMB-101","moa":"5-HT2C receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Bright Minds Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bright Minds Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Bright Minds Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Bright Minds Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Private Placement","leadProduct":"BMB-101","moa":"5-HT2C receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Bright Minds Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bright Minds Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bright Minds Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"NBI-827104","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neurocrine Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Neurocrine Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Surface Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Betamethasone","moa":"Glucocorticoid receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Surface Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Surface Oncology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Surface Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Neuraptive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"NTX-001","moa":"CBL-B","graph1":"Neurology","graph2":"Phase II","graph3":"Neuraptive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neuraptive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Neuraptive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Coya Therapeutics","sponsor":"Alzheimers Drug Discovery Foundation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2024","type":"Financing","leadProduct":"COYA 302","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Coya Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Coya Therapeutics \/ Alzheimers Drug Discovery Foundation","highestDevelopmentStatusID":"8","companyTruncated":"Coya Therapeutics \/ Alzheimers Drug Discovery Foundation"},{"orgOrder":0,"company":"Coya Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"COYA 302","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Coya Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Coya Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Coya Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Coya Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"COYA 302","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Coya Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Coya Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Coya Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Axcella Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"AXA1665","moa":"Ammonia handling pathway","graph1":"Neurology","graph2":"Phase II","graph3":"Axcella Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Axcella Health \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Axcella Health \/ Inapplicable"},{"orgOrder":0,"company":"Axcella Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"AXA1665","moa":"Ammonia handling pathway","graph1":"Neurology","graph2":"Phase II","graph3":"Axcella Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Axcella Health \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Axcella Health \/ Inapplicable"},{"orgOrder":0,"company":"Axcella Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"AXA1665","moa":"Ammonia handling pathway","graph1":"Neurology","graph2":"Phase II","graph3":"Axcella Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Axcella Health \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Axcella Health \/ Inapplicable"},{"orgOrder":0,"company":"Axcella Health","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"AXA1665","moa":"Ammonia handling pathway","graph1":"Neurology","graph2":"Phase II","graph3":"Axcella Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Axcella Health \/ J.P. Morgan","highestDevelopmentStatusID":"8","companyTruncated":"Axcella Health \/ J.P. Morgan"},{"orgOrder":0,"company":"ReAlta Life Sciences","sponsor":"Children\u2019S Research Holdings","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Series A Financing","leadProduct":"Pegtarazimod","moa":"Complement pathway","graph1":"Neurology","graph2":"Phase II","graph3":"ReAlta Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ReAlta Life Sciences \/ Children\u2019S Research Holdings","highestDevelopmentStatusID":"8","companyTruncated":"ReAlta Life Sciences \/ Children\u2019S Research Holdings"},{"orgOrder":0,"company":"ReAlta Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Pegtarazimod","moa":"Complement pathway","graph1":"Neurology","graph2":"Phase II","graph3":"ReAlta Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ReAlta Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ReAlta Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"ReAlta Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Pegtarazimod","moa":"Complement pathway","graph1":"Neurology","graph2":"Phase II","graph3":"ReAlta Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ReAlta Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ReAlta Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"ReAlta Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Pegtarazimod","moa":"Complement pathway","graph1":"Neurology","graph2":"Phase II","graph3":"ReAlta Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ReAlta Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ReAlta Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Pharmazz","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Sovateltide","moa":"ETB receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Pharmazz","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Pharmazz \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pharmazz \/ Inapplicable"},{"orgOrder":0,"company":"Pharmazz","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Sovateltide","moa":"ETB receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Pharmazz","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Pharmazz \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pharmazz \/ Inapplicable"},{"orgOrder":0,"company":"CervoMed","sponsor":"EIP Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Merger","leadProduct":"Neflamapimod","moa":"MAPK\/p38-alpha","graph1":"Neurology","graph2":"Phase II","graph3":"CervoMed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"CervoMed \/ EIP Pharma","highestDevelopmentStatusID":"8","companyTruncated":"CervoMed \/ EIP Pharma"},{"orgOrder":0,"company":"CervoMed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Neflamapimod","moa":"MAPK\/p38-alpha","graph1":"Neurology","graph2":"Phase II","graph3":"CervoMed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"CervoMed \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CervoMed \/ Inapplicable"},{"orgOrder":0,"company":"CervoMed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Neflamapimod","moa":"MAPK\/p38-alpha","graph1":"Neurology","graph2":"Phase II","graph3":"CervoMed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"CervoMed \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CervoMed \/ Inapplicable"},{"orgOrder":0,"company":"CervoMed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Neflamapimod","moa":"MAPK\/p38-alpha","graph1":"Neurology","graph2":"Phase II","graph3":"CervoMed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"CervoMed \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CervoMed \/ Inapplicable"},{"orgOrder":0,"company":"CervoMed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Neflamapimod","moa":"MAPK\/p38-alpha","graph1":"Neurology","graph2":"Phase II","graph3":"CervoMed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"CervoMed \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CervoMed \/ Inapplicable"},{"orgOrder":0,"company":"CervoMed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Neflamapimod","moa":"MAPK\/p38-alpha","graph1":"Neurology","graph2":"Phase II","graph3":"CervoMed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"CervoMed \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CervoMed \/ Inapplicable"},{"orgOrder":0,"company":"CervoMed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Neflamapimod","moa":"MAPK\/p38-alpha","graph1":"Neurology","graph2":"Phase II","graph3":"CervoMed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"CervoMed \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CervoMed \/ Inapplicable"},{"orgOrder":0,"company":"CervoMed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Neflamapimod","moa":"MAPK\/p38-alpha","graph1":"Neurology","graph2":"Phase II","graph3":"CervoMed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"CervoMed \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CervoMed \/ Inapplicable"},{"orgOrder":0,"company":"CervoMed","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Private Placement","leadProduct":"Neflamapimod","moa":"MAPK\/p38-alpha","graph1":"Neurology","graph2":"Phase II","graph3":"CervoMed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"CervoMed \/ RA Capital Management","highestDevelopmentStatusID":"8","companyTruncated":"CervoMed \/ RA Capital Management"},{"orgOrder":0,"company":"Cognition Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Zervimesine","moa":"Sigma-2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Cognition Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cognition Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cognition Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cognition Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Zervimesine","moa":"Sigma-2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Cognition Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cognition Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cognition Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cognition Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Zervimesine","moa":"Sigma-2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Cognition Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cognition Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cognition Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Lidocaine","moa":"NaV channel-alpha-subunit","graph1":"Neurology","graph2":"Phase II","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Sorrento Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sorrento Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Denali Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"BIIB122","moa":"LRRK2","graph1":"Neurology","graph2":"Phase II","graph3":"Denali Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Denali Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Denali Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Neuron23","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"NEU-411","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Neuron23","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neuron23 \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"8","companyTruncated":"Neuron23 \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Neuron23","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"NEU-411","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Neuron23","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neuron23 \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Neuron23 \/ Inapplicable"},{"orgOrder":0,"company":"AEON Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Prabotulinumtoxin A","moa":"ACh receptor","graph1":"Neurology","graph2":"Phase II","graph3":"AEON Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AEON Biopharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AEON Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"AEON Biopharma","sponsor":"Priveterra Acquisition Corp.","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2023","type":"Merger","leadProduct":"Prabotulinumtoxin A","moa":"ACh receptor","graph1":"Neurology","graph2":"Phase II","graph3":"AEON Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AEON Biopharma \/ Priveterra Acquisition Corp.","highestDevelopmentStatusID":"8","companyTruncated":"AEON Biopharma \/ Priveterra Acquisition Corp."},{"orgOrder":0,"company":"AEON Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2023","type":"Financing","leadProduct":"Prabotulinumtoxin A","moa":"ACh receptor","graph1":"Neurology","graph2":"Phase II","graph3":"AEON Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AEON Biopharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AEON Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"AEON Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2023","type":"Financing","leadProduct":"Prabotulinumtoxin A","moa":"ACh receptor","graph1":"Neurology","graph2":"Phase II","graph3":"AEON Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AEON Biopharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AEON Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Oxytocin","moa":"||CGRP receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Oxytocin","moa":"CGRP receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Oxytocin","moa":"CGRP receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Oxytocin","moa":"CGRP receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Oxytocin","moa":"CGRP receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Oxytocin","moa":"||CGRP receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Oxytocin","moa":"||CGRP receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"BHV-2100","moa":"TRPM3","graph1":"Neurology","graph2":"Phase II","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biohaven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biohaven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Autologous Mesenchymal Stem Cell Secreting Neurotrophic Factors Cell","moa":"Neurotrophic factor","graph1":"Neurology","graph2":"Phase II","graph3":"BrainStorm Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BrainStorm Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Autologous Mesenchymal Stem Cell Secreting Neurotrophic Factors Cell","moa":"Neurotrophic factor","graph1":"Neurology","graph2":"Phase II","graph3":"BrainStorm Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BrainStorm Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Autologous Mesenchymal Stem Cell Secreting Neurotrophic Factors Cell","moa":"Neurotrophic factor","graph1":"Neurology","graph2":"Phase II","graph3":"BrainStorm Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BrainStorm Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Autologous Mesenchymal Stem Cell Secreting Neurotrophic Factors Cell","moa":"Neurotrophic factor","graph1":"Neurology","graph2":"Phase II","graph3":"BrainStorm Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BrainStorm Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NeuroGenesis","sponsor":"Hadassah Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"NG-01","moa":"Stem cell proliferation","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroGenesis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"NeuroGenesis \/ Hadassah Medical Center","highestDevelopmentStatusID":"8","companyTruncated":"NeuroGenesis \/ Hadassah Medical Center"},{"orgOrder":0,"company":"NeuroGenesis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"NG-01","moa":"Stem cell proliferation","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroGenesis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"NeuroGenesis \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroGenesis \/ Inapplicable"},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"ATA188","moa":"T-cell receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Atara Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Atara Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Atara Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"ATA188","moa":"T-cell receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Atara Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Atara Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Atara Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"ATA188","moa":"T-cell receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Atara Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Atara Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Atara Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"ATA188","moa":"T-cell receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Atara Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Atara Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Atara Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"ATA188","moa":"T-cell receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Atara Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Atara Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Atara Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"ATA188","moa":"T-cell receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Atara Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Atara Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Atara Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"ATA188","moa":"T-cell receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Atara Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Atara Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Atara Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"ATA188","moa":"T-cell receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Atara Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Atara Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Atara Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"ATA188","moa":"T-cell receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Atara Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Atara Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Atara Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"ATA188","moa":"T-cell receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Atara Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Atara Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Atara Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"ATA188","moa":"T-cell receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Atara Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Atara Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Atara Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Emerald Health Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"EHP-101","moa":"PPA-gamma receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Emerald Health Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Emerald Health Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Emerald Health Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Emerald Health Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"EHP-101","moa":"PPA-gamma receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Emerald Health Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Emerald Health Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Emerald Health Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Denali Therapeutics","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"SAR443820","moa":"RIPK1","graph1":"Neurology","graph2":"Phase II","graph3":"Denali Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Denali Therapeutics \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Denali Therapeutics \/ Sanofi"},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Autologous Mesenchymal Stem Cell Secreting Neurotrophic Factors Cell","moa":"Neurotrophic factor","graph1":"Neurology","graph2":"Phase II","graph3":"BrainStorm Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BrainStorm Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Vidofludimus Calcium","moa":"DHODH","graph1":"Neurology","graph2":"Phase II","graph3":"Immunic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Immunic Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Immunic Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Vidofludimus Calcium","moa":"DHODH","graph1":"Neurology","graph2":"Phase II","graph3":"Immunic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Immunic Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Immunic Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Contineum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"PIPE-307","moa":"M1 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Contineum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Contineum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Contineum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Hope Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"HB-adMSCs","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Hope Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hope Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Hope Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Avidity Biosciences","sponsor":"Cowen","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody-oligonucleotide Conjugate","year":"2022","type":"Public Offering","leadProduct":"Del-Desiran","moa":"Transferrin-1 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Avidity Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avidity Biosciences \/ Cowen","highestDevelopmentStatusID":"8","companyTruncated":"Avidity Biosciences \/ Cowen"},{"orgOrder":0,"company":"Avidity Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody-oligonucleotide Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Del-Desiran","moa":"Transferrin-1 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Avidity Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avidity Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Avidity Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Avidity Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody-oligonucleotide Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Del-Desiran","moa":"Transferrin-1 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Avidity Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avidity Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Avidity Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Avidity Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody-oligonucleotide Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Del-Desiran","moa":"Transferrin-1 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Avidity Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avidity Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Avidity Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Avidity Biosciences","sponsor":"Adage Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody-oligonucleotide Conjugate","year":"2024","type":"Private Placement","leadProduct":"Del-Desiran","moa":"Transferrin-1 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Avidity Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avidity Biosciences \/ Adage Capital Partners","highestDevelopmentStatusID":"8","companyTruncated":"Avidity Biosciences \/ Adage Capital Partners"},{"orgOrder":0,"company":"Avidity Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody-oligonucleotide Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Del-Desiran","moa":"Transferrin-1 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Avidity Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avidity Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Avidity Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Avidity Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody-oligonucleotide Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Del-Desiran","moa":"Transferrin-1 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Avidity Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avidity Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Avidity Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Avidity Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody-oligonucleotide Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Del-Desiran","moa":"Transferrin-1 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Avidity Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avidity Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Avidity Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Avidity Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody-oligonucleotide Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Del-Desiran","moa":"Transferrin-1 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Avidity Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avidity Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Avidity Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Avidity Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody-oligonucleotide Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Del-Desiran","moa":"Transferrin-1 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Avidity Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avidity Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Avidity Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Avidity Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody-oligonucleotide Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Del-Desiran","moa":"Transferrin-1 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Avidity Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avidity Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Avidity Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Avidity Biosciences","sponsor":"Myotonic Dystrophy Clinical Research Network","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody-oligonucleotide Conjugate","year":"2020","type":"Collaboration","leadProduct":"Del-Desiran","moa":"Transferrin-1 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Avidity Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avidity Biosciences \/ Myotonic Dystrophy Clinical Research Network","highestDevelopmentStatusID":"8","companyTruncated":"Avidity Biosciences \/ Myotonic Dystrophy Clinical Research Network"},{"orgOrder":0,"company":"Neurogastrx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Metopimazine Mesylate","moa":"||Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Neurogastrx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neurogastrx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Neurogastrx \/ Inapplicable"},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Pilavapadin","moa":"AAK-1","graph1":"Neurology","graph2":"Phase II","graph3":"Lexicon pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Lexicon pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lexicon pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Pilavapadin","moa":"AAK-1","graph1":"Neurology","graph2":"Phase II","graph3":"Lexicon pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Lexicon pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lexicon pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Pilavapadin","moa":"AAK-1","graph1":"Neurology","graph2":"Phase II","graph3":"Lexicon pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Lexicon pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lexicon pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Pilavapadin","moa":"AAK-1","graph1":"Neurology","graph2":"Phase II","graph3":"Lexicon pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Lexicon pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lexicon pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pilavapadin","moa":"AAK-1","graph1":"Neurology","graph2":"Phase II","graph3":"Lexicon pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Lexicon pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lexicon pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Accure Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SPAIN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"ACT-01","moa":"Neurotrophic factor","graph1":"Neurology","graph2":"Phase II","graph3":"Accure Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Accure Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Accure Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Allay Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"NaV channel-alpha-subunit","graph1":"Neurology","graph2":"Phase II","graph3":"Allay Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Allay Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Allay Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Vitiprints","sponsor":"Tetra BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Agreement","leadProduct":"Tetrahydrocannabinol","moa":"CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Vitiprints","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Vitiprints \/ Tetra BioPharma","highestDevelopmentStatusID":"8","companyTruncated":"Vitiprints \/ Tetra BioPharma"},{"orgOrder":0,"company":"Ensysce Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Oxycodone Prodrug","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Ensysce Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ensysce Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ensysce Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Ensysce Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Private Placement","leadProduct":"Oxycodone Prodrug","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Ensysce Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ensysce Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ensysce Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Ensysce Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Partnership","leadProduct":"Oxycodone Prodrug","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Ensysce Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ensysce Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ensysce Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Aisa Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Cilnidipine","moa":"Calcium channel","graph1":"Neurology","graph2":"Phase II","graph3":"Aisa Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Aisa Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aisa Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Allay Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"NaV channel-alpha-subunit","graph1":"Neurology","graph2":"Phase II","graph3":"Allay Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Allay Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Allay Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Allay Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"NaV channel-alpha-subunit","graph1":"Neurology","graph2":"Phase II","graph3":"Allay Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Allay Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Allay Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Allay Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"NaV channel-alpha-subunit","graph1":"Neurology","graph2":"Phase II","graph3":"Allay Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Allay Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Allay Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Concentric Analgesics","sponsor":"Evolution Research Group","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Vocacapsaicin","moa":"||TRPV1","graph1":"Neurology","graph2":"Phase II","graph3":"Concentric Analgesics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Concentric Analgesics \/ Evolution Research Group","highestDevelopmentStatusID":"8","companyTruncated":"Concentric Analgesics \/ Evolution Research Group"},{"orgOrder":0,"company":"Concentric Analgesics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Vocacapsaicin","moa":"||TRPV1","graph1":"Neurology","graph2":"Phase II","graph3":"Concentric Analgesics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Concentric Analgesics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Concentric Analgesics \/ Inapplicable"},{"orgOrder":0,"company":"Concentric Analgesics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Financing","leadProduct":"Vocacapsaicin","moa":"||TRPV1","graph1":"Neurology","graph2":"Phase II","graph3":"Concentric Analgesics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Concentric Analgesics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Concentric Analgesics \/ Undisclosed"},{"orgOrder":0,"company":"Concentric Analgesics","sponsor":"University of Rochester Medical Center","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"Vocacapsaicin","moa":"||TRPV1","graph1":"Neurology","graph2":"Phase II","graph3":"Concentric Analgesics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Concentric Analgesics \/ University of Rochester Medical Center","highestDevelopmentStatusID":"8","companyTruncated":"Concentric Analgesics \/ University of Rochester Medical Center"},{"orgOrder":0,"company":"TLC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ropivacaine Hydrochloride","moa":"Na channel-alpha-subunit","graph1":"Neurology","graph2":"Phase II","graph3":"TLC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"TLC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"TLC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TLC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ropivacaine Hydrochloride","moa":"Na channel-alpha-subunit","graph1":"Neurology","graph2":"Phase II","graph3":"TLC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"TLC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"TLC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nevakar","sponsor":"Endo International","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Gabapentin","moa":"||CaV channel","graph1":"Neurology","graph2":"Phase II","graph3":"Nevakar","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Nevakar \/ Endo International","highestDevelopmentStatusID":"8","companyTruncated":"Nevakar \/ Endo International"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ACP-044","moa":"M1 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Acadia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Acadia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Latigo Biotherapeutics","sponsor":"Blue Owl Capital","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Series B Financing","leadProduct":"LTG-001","moa":"NaV1.8 Channel","graph1":"Neurology","graph2":"Phase II","graph3":"Latigo Biotherapeutics","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0.14999999999999999,"dosageForm":"Oral","sponsorNew":"Latigo Biotherapeutics \/ Blue Owl Capital","highestDevelopmentStatusID":"8","companyTruncated":"Latigo Biotherapeutics \/ Blue Owl Capital"},{"orgOrder":0,"company":"Teikoku Pharma USA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic-alpha-2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Teikoku Pharma USA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Teikoku Pharma USA \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Teikoku Pharma USA \/ Inapplicable"},{"orgOrder":0,"company":"MeiraGTx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"AAV-GAD","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"MeiraGTx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"MeiraGTx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MeiraGTx \/ Inapplicable"},{"orgOrder":0,"company":"MeiraGTx","sponsor":"Hologen","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Collaboration","leadProduct":"AAV-GAD","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"MeiraGTx","amount2":0.42999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0.42999999999999999,"dosageForm":"Infusion","sponsorNew":"MeiraGTx \/ Hologen","highestDevelopmentStatusID":"8","companyTruncated":"MeiraGTx \/ Hologen"},{"orgOrder":0,"company":"Neuraly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Exenatide","moa":"GLP-1 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Neuraly","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Neuraly \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Neuraly \/ Inapplicable"},{"orgOrder":0,"company":"Neuraly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Exenatide","moa":"GLP-1 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Neuraly","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Neuraly \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Neuraly \/ Inapplicable"},{"orgOrder":0,"company":"Neuraly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Exenatide","moa":"GLP-1 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Neuraly","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Neuraly \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Neuraly \/ Inapplicable"},{"orgOrder":0,"company":"Sio Gene Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"AXO-Lenti-PD","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Sio Gene Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sio Gene Therapies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sio Gene Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Sio Gene Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"AXO-Lenti-PD","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Sio Gene Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sio Gene Therapies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sio Gene Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Sio Gene Therapies","sponsor":"Oxford Biomedica","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"AXO-Lenti-PD","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Sio Gene Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sio Gene Therapies \/ Oxford Biomedica","highestDevelopmentStatusID":"8","companyTruncated":"Sio Gene Therapies \/ Oxford Biomedica"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"NBIb-1817","moa":"Aromatic-L-amino-acid decarboxylase","graph1":"Neurology","graph2":"Phase II","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracerebral Infusion","sponsorNew":"Neurocrine Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Neurocrine Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Voyager Therapeutics, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"NBIb-1817","moa":"Aromatic-L-amino-acid decarboxylase","graph1":"Neurology","graph2":"Phase II","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracerebral Infusion","sponsorNew":"Neurocrine Biosciences \/ Voyager Therapeutics, Inc","highestDevelopmentStatusID":"8","companyTruncated":"Neurocrine Biosciences \/ Voyager Therapeutics, Inc"},{"orgOrder":0,"company":"Voyager Therapeutics, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"NBIb-1817","moa":"Aromatic-L-amino-acid decarboxylase","graph1":"Neurology","graph2":"Phase II","graph3":"Voyager Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracerebral Infusion","sponsorNew":"Voyager Therapeutics, Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Voyager Therapeutics, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Voyager Therapeutics, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"VY-AADC","moa":"Aromatic-L-amino-acid decarboxylase","graph1":"Neurology","graph2":"Phase II","graph3":"Voyager Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracerebral Infusion","sponsorNew":"Voyager Therapeutics, Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Voyager Therapeutics, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Voyager Therapeutics, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"VY-AADC","moa":"Aromatic-L-amino-acid decarboxylase","graph1":"Neurology","graph2":"Phase II","graph3":"Voyager Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracerebral Infusion","sponsorNew":"Voyager Therapeutics, Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Voyager Therapeutics, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Voyager Therapeutics, Inc","sponsor":"Neurocrine Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"NBIb-1817","moa":"Aromatic-L-amino-acid decarboxylase","graph1":"Neurology","graph2":"Phase II","graph3":"Voyager Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracerebral Infusion","sponsorNew":"Voyager Therapeutics, Inc \/ Neurocrine Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"Voyager Therapeutics, Inc \/ Neurocrine Biosciences"},{"orgOrder":0,"company":"BlueRock Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Bemdaneprocel","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"BlueRock Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracerebral Injection","sponsorNew":"BlueRock Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BlueRock Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BlueRock Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Bemdaneprocel","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"BlueRock Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracerebral Injection","sponsorNew":"BlueRock Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BlueRock Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BlueRock Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Bemdaneprocel","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"BlueRock Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracerebral Injection","sponsorNew":"BlueRock Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BlueRock Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BlueRock Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Bemdaneprocel","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"BlueRock Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracerebral Injection","sponsorNew":"BlueRock Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BlueRock Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BlueRock Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Bemdaneprocel","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"BlueRock Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracerebral Injection","sponsorNew":"BlueRock Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BlueRock Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AskBio","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"AB-1005","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"AskBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intraputaminal Infusion","sponsorNew":"AskBio \/ Bayer AG","highestDevelopmentStatusID":"8","companyTruncated":"AskBio \/ Bayer AG"},{"orgOrder":0,"company":"AskBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"AB-1005","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"AskBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intraputaminal Infusion","sponsorNew":"AskBio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AskBio \/ Inapplicable"},{"orgOrder":0,"company":"AskBio","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"AB-1005","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"AskBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intraputaminal Infusion","sponsorNew":"AskBio \/ Bayer AG","highestDevelopmentStatusID":"8","companyTruncated":"AskBio \/ Bayer AG"},{"orgOrder":0,"company":"AskBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"AB-1005","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"AskBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intraputaminal Infusion","sponsorNew":"AskBio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AskBio \/ Inapplicable"},{"orgOrder":0,"company":"Alkahest","sponsor":"Grifols International","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"GRF6021","moa":"Lysine gingipain","graph1":"Neurology","graph2":"Phase II","graph3":"Alkahest","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alkahest \/ Grifols International","highestDevelopmentStatusID":"8","companyTruncated":"Alkahest \/ Grifols International"},{"orgOrder":0,"company":"Ventyx Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"VTX3232","moa":"NLRP3","graph1":"Neurology","graph2":"Phase II","graph3":"Ventyx Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ventyx Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ventyx Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Ventyx Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"VTX3232","moa":"NLRP3","graph1":"Neurology","graph2":"Phase II","graph3":"Ventyx Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ventyx Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ventyx Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Ventyx Biosciences","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"VTX3232","moa":"NLRP3","graph1":"Neurology","graph2":"Phase II","graph3":"Ventyx Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ventyx Biosciences \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Ventyx Biosciences \/ Sanofi"},{"orgOrder":0,"company":"Aevi Genomic Medicine","sponsor":"Cerecor","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"Rislenemdaz","moa":"GluN2B","graph1":"Neurology","graph2":"Phase II","graph3":"Aevi Genomic Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aevi Genomic Medicine \/ Cerecor","highestDevelopmentStatusID":"8","companyTruncated":"Aevi Genomic Medicine \/ Cerecor"},{"orgOrder":0,"company":"Synagile","sponsor":"Clintrex Research Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Etilevodopa","moa":"||D3 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Synagile","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Synagile \/ Clintrex Research Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Synagile \/ Clintrex Research Corporation"},{"orgOrder":0,"company":"Synagile","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Etilevodopa","moa":"||D3 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Synagile","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Synagile \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Synagile \/ Inapplicable"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"4-Chlorokynurenine","moa":"NMDA receptor","graph1":"Neurology","graph2":"Phase II","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"VistaGen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"VistaGen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ChromaDex, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"Nicotinamide Riboside Chloride","moa":"NAD","graph1":"Neurology","graph2":"Phase II","graph3":"ChromaDex, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ChromaDex, Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ChromaDex, Inc \/ Inapplicable"},{"orgOrder":0,"company":"CuraSen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"CST-103","moa":"||ADRB2","graph1":"Neurology","graph2":"Phase II","graph3":"CuraSen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"CuraSen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CuraSen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Neuropore Therapies","sponsor":"UCB Pharma S.A","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Minzasolmin","moa":"Alpha-synuclein misfolding","graph1":"Neurology","graph2":"Phase II","graph3":"Neuropore Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Neuropore Therapies \/ UCB Pharma S.A","highestDevelopmentStatusID":"8","companyTruncated":"Neuropore Therapies \/ UCB Pharma S.A"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"4-Chlorokynurenine","moa":"NMDA receptor","graph1":"Neurology","graph2":"Phase II","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"VistaGen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"VistaGen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"Risvodetinib Succinate","moa":"c-Abl kinase","graph1":"Neurology","graph2":"Phase II","graph3":"Inhibikase Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Inhibikase Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Inhibikase Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Risvodetinib Succinate","moa":"c-Abl kinase","graph1":"Neurology","graph2":"Phase II","graph3":"Inhibikase Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Inhibikase Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Inhibikase Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Risvodetinib Succinate","moa":"c-Abl kinase","graph1":"Neurology","graph2":"Phase II","graph3":"Inhibikase Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Inhibikase Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Inhibikase Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Risvodetinib Succinate","moa":"c-Abl kinase","graph1":"Neurology","graph2":"Phase II","graph3":"Inhibikase Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Inhibikase Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Inhibikase Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Thinkequity","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Public Offering","leadProduct":"Risvodetinib Succinate","moa":"c-Abl kinase","graph1":"Neurology","graph2":"Phase II","graph3":"Inhibikase Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Inhibikase Therapeutics \/ Thinkequity","highestDevelopmentStatusID":"8","companyTruncated":"Inhibikase Therapeutics \/ Thinkequity"},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Risvodetinib Succinate","moa":"c-Abl kinase","graph1":"Neurology","graph2":"Phase II","graph3":"Inhibikase Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Inhibikase Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"8","companyTruncated":"Inhibikase Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Risvodetinib Succinate","moa":"c-Abl kinase","graph1":"Neurology","graph2":"Phase II","graph3":"Inhibikase Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Inhibikase Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"8","companyTruncated":"Inhibikase Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Risvodetinib Succinate","moa":"c-Abl kinase","graph1":"Neurology","graph2":"Phase II","graph3":"Inhibikase Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Inhibikase Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Inhibikase Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Risvodetinib Succinate","moa":"c-Abl kinase","graph1":"Neurology","graph2":"Phase II","graph3":"Inhibikase Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Inhibikase Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Inhibikase Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Risvodetinib Succinate","moa":"c-Abl kinase","graph1":"Neurology","graph2":"Phase II","graph3":"Inhibikase Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Inhibikase Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Inhibikase Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Risvodetinib Succinate","moa":"c-Abl kinase","graph1":"Neurology","graph2":"Phase II","graph3":"Inhibikase Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Inhibikase Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Inhibikase Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Risvodetinib Succinate","moa":"c-Abl kinase","graph1":"Neurology","graph2":"Phase II","graph3":"Inhibikase Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Inhibikase Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Inhibikase Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Risvodetinib Succinate","moa":"c-Abl kinase","graph1":"Neurology","graph2":"Phase II","graph3":"Inhibikase Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Inhibikase Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Inhibikase Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Risvodetinib Succinate","moa":"c-Abl kinase","graph1":"Neurology","graph2":"Phase II","graph3":"Inhibikase Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Inhibikase Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Inhibikase Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Risvodetinib Succinate","moa":"c-Abl kinase","graph1":"Neurology","graph2":"Phase II","graph3":"Inhibikase Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Inhibikase Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Inhibikase Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Risvodetinib Succinate","moa":"c-Abl kinase","graph1":"Neurology","graph2":"Phase II","graph3":"Inhibikase Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Inhibikase Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Inhibikase Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Risvodetinib Succinate","moa":"c-Abl kinase","graph1":"Neurology","graph2":"Phase II","graph3":"Inhibikase Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Inhibikase Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Inhibikase Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Risvodetinib Succinate","moa":"c-Abl kinase","graph1":"Neurology","graph2":"Phase II","graph3":"Inhibikase Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Inhibikase Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Inhibikase Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Risvodetinib Succinate","moa":"c-Abl kinase","graph1":"Neurology","graph2":"Phase II","graph3":"Inhibikase Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Inhibikase Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Inhibikase Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Risvodetinib Succinate","moa":"c-Abl kinase","graph1":"Neurology","graph2":"Phase II","graph3":"Inhibikase Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Inhibikase Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Inhibikase Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Inhibikase Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Risvodetinib Succinate","moa":"c-Abl kinase","graph1":"Neurology","graph2":"Phase II","graph3":"Inhibikase Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Inhibikase Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Inhibikase Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aptinyx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"NYX-458","moa":"NMDA receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Aptinyx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aptinyx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aptinyx \/ Inapplicable"},{"orgOrder":0,"company":"Aptinyx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"NYX-458","moa":"NMDA receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Aptinyx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aptinyx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aptinyx \/ Inapplicable"},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Blarcamesine","moa":"Sigma-1 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Anavex Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Anavex Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Anavex Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Blarcamesine","moa":"Sigma-1 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Anavex Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Anavex Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Anavex Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Blarcamesine","moa":"Sigma-1 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Anavex Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Anavex Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Anavex Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Blarcamesine","moa":"Sigma-1 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Anavex Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Anavex Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Anavex Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Blarcamesine","moa":"Sigma-1 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Anavex Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Anavex Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Anavex Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Michael J. Fox Foundation for Parkinson\u2019s Research","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Funding","leadProduct":"Blarcamesine","moa":"Sigma-1 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Anavex Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Anavex Life Sciences \/ Michael J. Fox Foundation for Parkinson\u2019s Research","highestDevelopmentStatusID":"8","companyTruncated":"Anavex Life Sciences \/ Michael J. Fox Foundation for Parkinson\u2019s Research"},{"orgOrder":0,"company":"Sage Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"SAGE-718","moa":"NMDA receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Sage Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Softgel Capsule","sponsorNew":"Sage Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sage Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"CNM-Au8","moa":"Cellular energy production","graph1":"Neurology","graph2":"Phase II","graph3":"Clene Nanomedicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Clene Nanomedicine \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Clene Nanomedicine \/ Inapplicable"},{"orgOrder":0,"company":"Denali Therapeutics","sponsor":"Biogen","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"BIIB122","moa":"LRRK2","graph1":"Neurology","graph2":"Phase II","graph3":"Denali Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Denali Therapeutics \/ Biogen","highestDevelopmentStatusID":"8","companyTruncated":"Denali Therapeutics \/ Biogen"},{"orgOrder":0,"company":"Denali Therapeutics","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"BIIB122","moa":"LRRK2","graph1":"Neurology","graph2":"Phase II","graph3":"Denali Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Denali Therapeutics \/ Biogen","highestDevelopmentStatusID":"8","companyTruncated":"Denali Therapeutics \/ Biogen"},{"orgOrder":0,"company":"Denali Therapeutics","sponsor":"Biogen","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"BIIB122","moa":"LRRK2","graph1":"Neurology","graph2":"Phase II","graph3":"Denali Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Denali Therapeutics \/ Biogen","highestDevelopmentStatusID":"8","companyTruncated":"Denali Therapeutics \/ Biogen"},{"orgOrder":0,"company":"Denali Therapeutics","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"BIIB122","moa":"LRRK2","graph1":"Neurology","graph2":"Phase II","graph3":"Denali Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Denali Therapeutics \/ Biogen","highestDevelopmentStatusID":"8","companyTruncated":"Denali Therapeutics \/ Biogen"},{"orgOrder":0,"company":"Pfizer CentreOne","sponsor":"Enterin","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"Squalamine phosphate","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase II","graph3":"Pfizer CentreOne","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer CentreOne \/ Enterin","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer CentreOne \/ Enterin"},{"orgOrder":0,"company":"Enterin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Squalamine phosphate","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase II","graph3":"Enterin","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Enterin \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Enterin \/ Inapplicable"},{"orgOrder":0,"company":"Enterin","sponsor":"Parkinson\u2019s Virtual Biotech","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"Squalamine phosphate","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase II","graph3":"Enterin","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Enterin \/ Parkinson\u2019s Virtual Biotech","highestDevelopmentStatusID":"8","companyTruncated":"Enterin \/ Parkinson\u2019s Virtual Biotech"},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Fosgonimeton","moa":"HGF receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Athira Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Athira Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Athira Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fosgonimeton","moa":"HGF receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Athira Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Athira Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Athira Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Neuraptive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"NTX-001","moa":"CBL-B","graph1":"Neurology","graph2":"Phase II","graph3":"Neuraptive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Neuraptive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Neuraptive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Neuraptive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"NTX-001","moa":"CBL-B","graph1":"Neurology","graph2":"Phase II","graph3":"Neuraptive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Neuraptive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Neuraptive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Neuraptive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"NTX-001","moa":"CBL-B","graph1":"Neurology","graph2":"Phase II","graph3":"Neuraptive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Neuraptive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Neuraptive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Neuraptive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"NTX-001","moa":"CBL-B","graph1":"Neurology","graph2":"Phase II","graph3":"Neuraptive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Neuraptive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Neuraptive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Neuraptive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"NTX-001","moa":"CBL-B","graph1":"Neurology","graph2":"Phase II","graph3":"Neuraptive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Neuraptive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Neuraptive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Neuraptive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"NTX-001","moa":"CBL-B","graph1":"Neurology","graph2":"Phase II","graph3":"Neuraptive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Neuraptive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Neuraptive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Hesperos","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Riliprubart","moa":"C1 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Hesperos","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Hesperos \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Hesperos \/ Sanofi"},{"orgOrder":0,"company":"Nuvig Therapeutics","sponsor":"Sanofi Ventures","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Series B Financing","leadProduct":"NVG-2089","moa":"Fc-gamma receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Nuvig Therapeutics","amount2":0.16,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0.16,"dosageForm":"Undisclosed","sponsorNew":"Nuvig Therapeutics \/ Sanofi Ventures","highestDevelopmentStatusID":"8","companyTruncated":"Nuvig Therapeutics \/ Sanofi Ventures"},{"orgOrder":0,"company":"HemoShear Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"HST5040","moa":"CoA","graph1":"Neurology","graph2":"Phase II","graph3":"HemoShear Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"HemoShear Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"HemoShear Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"HemoShear Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"HST5040","moa":"CoA","graph1":"Neurology","graph2":"Phase II","graph3":"HemoShear Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"HemoShear Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"HemoShear Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Rapport Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"RAP-219","moa":"AMPA receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Rapport Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Rapport Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Rapport Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Praxis Precision Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Relutrigine","moa":"NaV Channel","graph1":"Neurology","graph2":"Phase II","graph3":"Praxis Precision Medicines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Praxis Precision Medicines \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Praxis Precision Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Xenon Pharmaceuticals Inc","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"NBI-921352","moa":"Nav1.6 channel","graph1":"Neurology","graph2":"Phase II","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Neurocrine Biosciences \/ Xenon Pharmaceuticals Inc","highestDevelopmentStatusID":"8","companyTruncated":"Neurocrine Biosciences \/ Xenon Pharmaceuticals Inc"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"NBI-921352","moa":"Nav1.6 channel","graph1":"Neurology","graph2":"Phase II","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Neurocrine Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Neurocrine Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Xenon Pharmaceuticals Inc","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"NBI-921352","moa":"Nav1.6 channel","graph1":"Neurology","graph2":"Phase II","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Neurocrine Biosciences \/ Xenon Pharmaceuticals Inc","highestDevelopmentStatusID":"8","companyTruncated":"Neurocrine Biosciences \/ Xenon Pharmaceuticals Inc"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Vixotrigine","moa":"NaV Channel","graph1":"Neurology","graph2":"Phase II","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Transposon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"TPN-101","moa":"Reverse transcriptase","graph1":"Neurology","graph2":"Phase II","graph3":"Transposon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Transposon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Transposon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Transposon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"TPN-101","moa":"Reverse transcriptase","graph1":"Neurology","graph2":"Phase II","graph3":"Transposon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Transposon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Transposon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Supernus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Fordine","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Supernus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Supernus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Supernus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"||CB1 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"IGC Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"IGC Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"IGC Pharma \/ Inapplicable"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"||CB1 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"IGC Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"IGC Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"IGC Pharma \/ Inapplicable"},{"orgOrder":0,"company":"IGC Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"||CB1 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"IGC Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"IGC Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"IGC Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Ionis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"BIIB080","moa":"Tau aggregation","graph1":"Neurology","graph2":"Phase II","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Biogen \/ Ionis Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Biogen \/ Ionis Pharmaceuticals"},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Vidofludimus Calcium","moa":"Nurr1\/DHODH","graph1":"Neurology","graph2":"Phase II","graph3":"Immunic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Immunic Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Immunic Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Spinogenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"SPG302","moa":"Synaptogenesis","graph1":"Neurology","graph2":"Phase II","graph3":"Spinogenix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Spinogenix \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Spinogenix \/ Inapplicable"},{"orgOrder":0,"company":"Nuvig Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"NVG-2089","moa":"Fc-gamma receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Nuvig Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Nuvig Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Nuvig Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bright Minds Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"BMB-101","moa":"5-HT2C receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Bright Minds Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Liquid","sponsorNew":"Bright Minds Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Bright Minds Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"ABLi Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Risvodetinib","moa":"c-Abl kinase","graph1":"Neurology","graph2":"Phase II","graph3":"ABLi Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ABLi Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ABLi Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Lithium Salicylate Proline","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Alzamend Neuro \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alzamend Neuro \/ Inapplicable"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Lithium Salicylate Proline","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Alzamend Neuro \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alzamend Neuro \/ Inapplicable"},{"orgOrder":0,"company":"Endurance Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"T-168","moa":"PGC-1-alpha\/TFEB","graph1":"Neurology","graph2":"Phase II","graph3":"Endurance Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Endurance Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Endurance Bio \/ Inapplicable"},{"orgOrder":0,"company":"Allay Therapeutics","sponsor":"Lightstone Ventures","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Series D Financing","leadProduct":"Bupivacaine","moa":"NaV channel-alpha-subunit","graph1":"Neurology","graph2":"Phase II","graph3":"Allay Therapeutics","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0.059999999999999998,"dosageForm":"Implant","sponsorNew":"Allay Therapeutics \/ Lightstone Ventures","highestDevelopmentStatusID":"8","companyTruncated":"Allay Therapeutics \/ Lightstone Ventures"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Lead Product(s) : Squalamine phosphate

                          Therapeutic Area : Neurology

                          Study Phase : Phase II

                          Sponsor : Enterin

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          Details : Enterin completed the first human clinical trials for ENT-01 which demonstrated that oral administration of its treatment has restored function of the nervous system of the gastrointestinal tract in Parkinson’s patients.

                          Product Name : ENT-01

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          March 28, 2022

                          Lead Product(s) : Squalamine phosphate

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase II

                          Sponsor : Enterin

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          Pfizer centreOne

                          02

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : AL001 is a novel lithium-delivery system that has the potential to provide the benefits of marketed lithium salts while mitigating or avoiding currently experienced toxicities associated with lithium.

                          Product Name : AL001

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          May 13, 2025

                          Lead Product(s) : Lithium Salicylate Proline

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : ABLi-148009 (risvodetinib) is a potent, selective small-molecule inhibitor of the non-receptor c-Abl kinases, designed for once-daily oral use that targets Parkinson’s disease.

                          Product Name : ABLi-148009

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          May 12, 2025

                          Lead Product(s) : Risvodetinib

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : IMU-838 (vidofludimus calcium) is an orally administered, Nurr1/DHODH modulator, being investigated for the treatment of progressive multiple sclerosis (PMS).

                          Product Name : IMU-838

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          April 30, 2025

                          Lead Product(s) : Vidofludimus Calcium

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : RNS60 activates intracellular signaling pathways to increase mitochondrial biogenesis and function and reduce inflammation. It is being investigated for acute ischemic stroke.

                          Product Name : RNS60

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          April 09, 2025

                          Lead Product(s) : RNS60

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : BIIB080 is an investigational antisense oligonucleotide (ASO) therapy designed to target microtubule-associated protein tau (MAPT) mRNA to reduce the production of tau protein.

                          Product Name : IONIS-MAPTRx

                          Product Type : Oligonucleotide

                          Upfront Cash : Inapplicable

                          April 02, 2025

                          Lead Product(s) : BIIB080

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase II

                          Sponsor : Ionis Pharmaceuticals

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : IGC-AD1 is the first natural cannabis-based THC formulation, which is being evaluated for the treatment of agitation in dementia from alzheimer’s disease.

                          Product Name : IGC-AD1

                          Product Type : Controlled Substance

                          Upfront Cash : Inapplicable

                          April 01, 2025

                          Lead Product(s) : Tetrahydrocannabinol,Melatonin

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : SPG302 is a once-a-day pill being developed as a regenerative treatment for schizophrenia that has the unique ability restore synapses.

                          Product Name : SPG302

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          March 31, 2025

                          Lead Product(s) : SPG302

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : IGC-AD1 is a cannabinoid-based partial CB1 receptor agonist with anti-neuroinflammatory and neuroprotective properties. It is being evaluated for the treatment of dementia due to Alzheimer's disease.

                          Product Name : IGC-AD1

                          Product Type : Controlled Substance

                          Upfront Cash : Inapplicable

                          March 26, 2025

                          Lead Product(s) : Tetrahydrocannabinol,Melatonin

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : Lomecel-B is a preparation of multipotent stem & progenitor cells isolated from bone marrow of young healthy adults. It is being evaluated for the treatment of mild alzheimer's disease.

                          Product Name : Lomecel-B

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Inapplicable

                          March 20, 2025

                          Lead Product(s) : Laromestrocel

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank